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Abstract
Phenotypic and Biomarker Expression Analysis of Human Urinary
Bladder Cancers
Background & Objective:
Novel biomarkers are required to distinguish potentially aggressive
urothelial bladder cancers from those in which interventional management
may be delayed. This thesis tested the hypothesis that accurate biomarker
staging would help identify different urothelial cancer pathways to provide
essential prognostic information in the pathological assessmentof these
malignancies.
Design & Setting:
A case-control study with comparative statistical evaluation of biomarker
expression andclinical progression in a routine surgical pathology
laboratory setting to evaluate the aggressive potential of newly-diagnosed
bladder neoplasms.
Patients & Methods:
312 bladder biopsy specimens were examined from 131 unselected patients
(87 males and 44 females) and comprising 75% cancers, 4% inflammatory,
8% histologically unremarkable and 13% histological normal urothelial
tissue as controls. Tissues were stained immunohistochemically for
expression of a panel of 12 biomarkers (Ki-67, p53, Rb, p21, p16, Bcl-X_,
Bcl-2, PTEN, ERa, ERB, ErbB-2 and Hsp-27). Staining was dichotomised
for analysis using non-parametric statistics. Expression data were compared
with histological stage.
Results:
Potential biomarkers Ki-67, p53, Bcl-2, Bcl-X_, ERB and ErbB-2 were
found to be significantly different between different tumourstages.
Significant Up-regulation of Ki-67, p53, p16 and PTENwithloss of Bcl-2,
Rb and ERB wasseen in non-muscle invasive urothelial cancer. Significant
down-regulation of p16, erbB-2 & PTEN wasseen with muscle invasive
urothelial cancer. Inflammatory urothelium and urothelium with a history of
urothelial carcinoma expressed abnormalexpression profiles despite being
histologically normal.
Conclusions:
Mutated p53 & Rbidentify high-risk non-muscle invasive urothelial cancer.
ErbB-2 & bcl-2 distinguish neoplasia from benign disease. Hsp-27 is useful
in distinguishing microscopic invasion (pT1) from non-invasive (pTa)
malignancies. Thefindings of this study suggest a significant secondhit in
muscle invasive urothelial carcinoma with loss of Ki-67, ERB and erbB-2
and Bcl-X,, gain. Phenotypicclassification of urothelial cancer could be
based on the four-group expression patterns of p53 and Rb. Thereafter, p21,
p16, erbB-2, bcl-2 and PTEN would be useful in sub-group analysis.
Chapter 1
HumanUrinary bladder Carcinoma:
--Epidemiology, Staging and Risk Factors
Humanbladder carcinomais a debilitating disease that is often
underestimated in terms of incidence, morbidity to the patients and
mortality. Worldwide, urinary bladder cancer accounts for over 350,000
new cancers each year being the ninth most commoncancer; with 90% of
these being urothelial carcinoma. The majority (75-85%)of the urothelial
carcinomasare non-muscle invasiveat first diagnosis. Despite this, there
were over 145,000 deaths'. The prognosis remains good with non-muscle
invasive urothelial carcinoma despite a high recurrence rate (30%-80%).
However, up to 45% progress to muscle invasive disease in 5 years” °,
Progression at 5years is more likely to occur in patients who had high grade
disease at diagnosis or concomitant carcinoma in-situ’. Subsequent5-year
survival rates dramatically lower (<50%) despite radical treatment.
Therefore efforts to improve outcomeare centred on modifying/ eradicating
causative factors as well as attempts to improve early diagnosis and
prevention of recurrence and progression.
Non-muscle invasive urothelial carcinomais a chronic disease with a
variable behavioural pattern thereby requiring repeated treatment, frequent
follow-up makingthecostper patient from diagnosis to death the highest of
all cancers. Non-muscle invasive urothelial carcinomais a majordrain on
the health economic burdenandisalso likely to affect the quality oflife of
patients with bladdercancer. Urothelial carcinomahasa short/unknown
prodromal period. Therefore screening tests have been sub optimal. A
majority of the patients who present with bladder cancer have haematuria
(mainly frank). A low minority of patients have incidentally diagnosed
disease with radiological investigations. Hence, mostclinicians and public
health scientists have turned their attention towards understanding the
epidemiological behaviorofthis disease.
In this chapter, I intend to outline the evidence available so far on global
occurrence, incidence and mortality of urinary bladder cancerand discuss
the epidemiological behaviorof this disease. The World Health
Organisation/ International Society of Urologic Pathologists (WHO/ISUP)
consensusclassification of urothelial lesions of the urinary bladderis also
discussed.
1.1.1 Incidence
Epidemiological studies’ have failed to show any significant patterns with
no comparable urothelial carcinoma incidence between the developing
countries and the developed world including Japan. Majority of the urinary
bladder tumours were in men (3-times). This marked genderdifference is
explained to a certain extent by smoking habits and occupation. There was a
higherincidence in the developed world with the higher proportion reported
in Europe and North America®. Work place exposure is the given
explanation, estimated to be responsible for up to a quarter of newly
diagnosed bladder cancers’. In the developing world, industrialisation, less
stringent health and safety criteria and an increasing number of smokers
together with the population boom haveresulted in an increasing incidence
especially in the BRIC countries of Brazil, Russia, India and China. The
consequencesof this demographic shift will only become apparent over the
next decade or two. However, the methodology in reporting is circumspect
with differences/lack of registering new tumours (Africa and Asia) as well
as none/variable coding of low grade tumours (pTa) in the western world
making direct comparisonsdifficult.
In the European Union, bladdercancer incidence varies across the region
with highest incidence (>30/100, 000) among menin northern Italy and
Spain. The majority of Northern and Eastern Europe have seen lowerrates.
United Kingdom, France and Germany have intermediate incidence °.
However, the ageing population presents a major obstacle with studies
showingan increased incidence with age. Shiet al. reported an increase in
the percentage of female patients with the non-muscle invasive urothelial
carcinomawith increasing age; incidence increasing from | in 4 in the under
40s to 1 in 2 in the over 60s*. Other studies have reported an increased risk
of bladder cancer in post-menopausal women’. Hormonallevels particularly
oestrogen falls with menopause which suggesta protective effect of
oestrogen on the bladder; also shownto inhibit the growth and development
murine bladder cancer”.
1.1.2 Mortality
Age standardised mortality rates (worldwide) are 2-10/100,000 males and
0.5-4/100,000 females '’. There has beenlessvariability in mortality figures
worldwide (Figure 1.1). However, the consequenceofan increasing urinary
bladder cancerincidence in the developing worldis nottoo difficult to
fathom. These countries already have an overstretched and underfunded
health infrastructure. Diseases such as urinary bladder cancer with a high
per patient cost and morbidity can envisage a sharp increase in mortality.
In Europe, mortality rates were relatively stable until the early 90s with
reported rates of 7/100,000 in men and 1.5/100,000 andthen declined by
more than 21% in next ten years. This could be due tostricter industrial
regulations, earlier diagnosis especially in men and a reduction in smoking.
However, this is variable with increased incidence and mortality rates in
Poland and Denmark’*. (Figure 1.2)
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Figure 1.1: World--Age standardized incidence and mortality rates for
urinary bladder cancer per 100,000'°
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Figure 1.2: Age-standardised (European) incidencerates by sex-2002
estimates!*
In the British Isles, urinary bladder cancer remains the fourth commonest
cancer in men and the tenth most common cancer in women with more than
10 000 newcasesreported in 2005 and almost 5000 deaths from urinary
bladder cancer in 2007'*. Mortality rates are markedly higherin the older
age groups with 90% of both male and female deaths occurring after
65years of age. Cancer research UK"have analysed mortality statistics over
a 35year period. Male mortality is reported to have fallen by 30% from 12.2
per 100 000 population in 1992 to 8.1 per 100 000 population in 2007
(Figure 1.3).
A 60% decrease in mortality from 12.8 to 5.0 per 100 000 population was
noticed in men aged between 45 and 64 years. In females, the reduction in
mortality rates are less marked with rates reducing from 3.5 per 100 000 in
the 1970s/early 1980s to 2.8 per 100 000 in 2007 (Figure 1.4).
Again, the largest reduction has been seen in the 45-64 age group with rates
falling from 3.8 per 100 000 in 70s/80sto 2.0 per 100 000 in 2001. One of
the confounding factors in epidemiological studies is the differences in
registration and reporting of low grade tumours. This makes accurate
comparisons between countries imprecise.
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Figure 1.3: Age-specific mortality rates, males, UK 1971-2007
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1.2: WHO/ ISUP Consensusclassification:
The difficulties in accurate histological reporting were recognised by the
World Health Organisation (WHO)andthe International Society of
Urological Pathologists (ISUP). In 1998, these two groups jointly published
the WHO/ISUPconsensusclassification of urothelial (transitional cell)
urinary bladder neoplasms. The benefit of this modified system was a
universally acceptable classification which also took into consideration the
nomenclature of pre-neoplastic lesions. In 2004, this classification system
was adopted in Pathology and Genetics of Tumours of the Urinary System
and Male Genital Organs, one of a series of WHO Blue Booksfor the
classification of tumors'”. This version is knownas the 2004 WHO
classification andis essentially the same as the 1998 WHO/ISUP system
(Table 1.1).
The WHO1973 and WHO/ISUP 1998classifications are two duplicate
systemsthat remain the bench markreporting tools used in histopathology
to characterise urothelial lesions. These systemsare not a direct correlation
except at the extremesofclassification where this one-to-one correlation
holds true.
11
 e Normal
o Normal*
e Hyperplasia
o Flat hyperplasia
o Papillary hyperplasia
e Flat lesions with atypia
o Reactive (inflammatory) atypia
o Dysplasia
o Carcinomainsitu*
e Papillary neoplasms
o Papilloma
o PUNLMP(papillary urothelial neoplasms of low
malignantpotential)
o Papillary carcinoma, low grade
o Papillary carcinoma, high grade
*May include cases formerly diagnosed as mild dysplasia
*Mayincludecases formerly diagnosed as severe dysplasia 
 
Table 1.1: WHO/ISUPconsensusclassification (2004) of urothelial
- 16lesions
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1.2.1: Normal urothelium:
The urothelium is routinely exposed to a wide range of toxins that are
excreted as a result of the normal physiologic functions of the kidney and
the storage role ofthe urinary bladder. A slight degree of architectural
turbulence could be considered normal (Figure 1.5). Over the years, there
has been a tendencyto over-diagnose ‘dysplasia’. The consensus group
decided to drop the term “mild dysplasia” deciding that theseflat lesions
with minimal cytological atypia and architectural disarray should be
described as normal. The reason behindthisclarification is that these lesions
without cytological atypia lack premalignantpotential.
1.2.2: Hyperplasia
1.2.2.1: Flat urothelial hyperplasia:
This is defined as markedly thickened mucosa but withoutcellular atypia
(Figure 1.6). The previous suggestion for the urothelium to exceed seven
cell layers by thickness'’ has been amendedto requiring obvious urothelial
thickening. Thereis no data to suggestthat this lesion is pre-neoplastic but
can be seen in adjacent mucosa to low-gradelesions.
1.2.2.2: Papillary urothelial hyperplasia:
These are asymptomatic lesions usually found during cystoscopic
surveillance for urothelial carcinoma’.It is characterised by variable
thickness urothelium with fluctuating growth (Figures 1.7, 1.8).
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Figure 1.5: Normal urothelium. Slight nuclearirregularity still falls within
the spectrum of normal urothelium.
 
Figure 1.6: Flat Urothelial Hyperplasia
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 Figure 1.7: Papillary Urothelial Hyperplasia withoutatypia
Figure 1.8: Papillary urothelial hyperplasia without atypia. Nuclear
architecture and cytological arrangement appear normal
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Theselesionsdistinctly lack fibrovascular cores. This diagnosis per se does
notplace patient at risk of developing carcinomabut cystoscopic follow
up is advised. However,if this is diagnosed in patients with a history of
papillary neoplasms,it is associated with an increasedrisk of recurrence of
papillary carcinoma'®,
1.2.3: Flat lesions with Atypia:
Patients with reactive atypia havea history of intravesical therapy, calculi or
instrumentation with consequent inflammation. The WHO/ISUP (1998)
clarified the histological picture for reactive (inflammatory) atypia from
dysplasia. Reactive (inflammatory) atypia consists of nuclear abnormalities
occurring in inflamed urothelium either acute or chronic. This is
characterised by a mild increase in nuclear size and central prominent
nucleoli within a vesicular nucleus (Figure 1.9). There is absence of nuclear
hyperchromasia, pleomorphism and chromatin irregularity. Mitotic figures
maybe frequently present.
1.2.4: Dysplasia
Dysplasia or Low-grade intraurothelial neoplasia refers to urothelial lesions
with noticeable significant architectural disarray and abnormalcellular
structure'” (Figure 1.10).
Studies have shownthat dysplasia could be a precursor of invasive
carcinoma~” and aretypically seen in bladders with urothelial neoplasia and
uncommonin bladders without it),
16
 
Figure 1.9: Reactive Urothelial atypia
 
Figure 1.10: Urothelial Dysplasia
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Managementof dysplasia is varied among differing urologists. It is usual
practice to treat dysplasia with intravesical chemotherapy only if it occurs in
association with and/ or a history of urothelial neoplasia or carcinomainsitu
as these patients are at a higher risk of recurrence and progression” ee
However,urothelial dysplasia is a precursor lesion to invasive carcinoma in
somepatients. This is supported by findings of concurrent dysplasia and
carcinoma, absence of dysplasia in non-neoplastic bladders and the genetic
ee . : : -, 1921-23similarities with carcinomain-situ 921-2 7
1.2.5: Carcinomain situ (CIS):
The WHO/ISUPsystem has attempted toclarify the histological confusion
on carcinomain situ. Carcinomain situ or high-grade intraurothelial
neoplasia is a flat urothelial lesion which in the past has been labelled as
marked atypia or severe dysplasia.It is considered a high-grade lesion and a
defined precursor of invasive carcinoma;characterised by cells with large,
irregular, hyperchromatic nuclei and nuclear membraneirregularities
(Figure 1.11). This maybe present throughthe entire epithelial thickness.
The Consensus committee’® have suggested that carcinomainsitu is often
under diagnosed and offer suggestions why:
1. Full thickness cytologic atypia is not required for a diagnosis of
carcinomain situ. Patterns of carcinomain situ include those with
scattered carcinomain situ cells, Pagetoid spread of carcinomain
situ, and cases wherethe fragile epithelium may be disrupted either
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spontaneously or by the biopsyso that only a few residual cancer
cells remain on the surface (clinging carcinomain situ)”°
2. Carcinomain situ cells do not always have a high
nuclear/cytoplasmic ratio
3. An umbrella cell layer maystill be present in carcinomainsitu
4. There is a spectrum of cytologic atypia within carcinomainsitu.
Howeversub-classifying carcinomain situ based onthe cellular
ploemorphism should be avoided as this should be compared in
conjunction with surrounding normal urothelium
In making the diagnosis of carcinomain situ, the most important parameters
are the nuclear features.
1.2.6: Papillary Urothelial Neoplasms:
Prior to the Consensuscriteria being developed in 1998 and consequently
confirmed in 2004, there were varied yardsticks in defining papilloma and
low grade papillary carcinomaas well as in grading papillary urothelial
carcinoma. Thearchitectural criteria describing the various grades in the sub
classification is one of the important benefits from the WHO/ISUPsystem.
Thesecriteria are based on the papillae structure and cellular features. The
cellular features include nuclear size and shape, chromatin content, nucleoli,
mitoses and umbrella cells. The classification system brought in
advantageoussimilarity with cytology.
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Figure 1.11: Carcinomain situ with hyperchromatic nuclei and numerous
mitotic figures (arrows)
 
Figure 1.12: Benign Urothelial Papilloma
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1.2.7: Papilloma:
Strict histological criteria have been defined for the diagnosis of papilloma.
The defined appearance would be discrete papillary growth with a central
fibrovascular core and lined by normal looking urothelium (Figure 1.12).
This is a rare benign condition exemplified as small isolated growths
primarily in youngerpatients. Inverted papillomais a variant of papilloma
but with somesimilar features of the exophytic type. Resection is curative in
both with very low recurrence rates”.
1.2.8: Papillary Urothelial Neoplasms of Low malignant potential
(PUNLMP):
Theseare papillary urothelial lesions that do not havecellular features of
malignancy but have thickened urothelium and/or nuclear enlargement
(Figures 1.13, 1.14). There is no nuclear dysmorphism unlike low grade
papillary tumours. In the PUNLMPlesions,the distinct difference from
papillomasis a thicker urothelium and with enlarged nuclei. Mitotic figures
if presentare limited to the basal layer. The importance ofthis group
labelled as neither benign nor overtly malignant stems from the increased
risk of developing recurrent or new papillary lesions which are usually of
the same histology but lower rates than low-grade papillary cancers”**”,
However, occasionally the subsequentlesions are of higher grade and could
progress’. This category gives the clinician the opportunity not to label a
patient as with cancer butensures that a closer follow-up regimeis
instituted.
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Figure 1.13: Plain view ofpapillary urothelial neoplasm of low malignant
potential
 
Figure 1.14: Cytologic appearancesofpapillary urothelial neoplasm of low
malignant potential
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1.2.9: Low-grade & High-grade papillary urothelial carcinoma:
Oneofthe significant pitfalls of the WHO 1973classification system was
the intermediate group (WHOgrade 2) which wasoften the default
diagnosis for pathologists In an attempt to simplify this issue, the
WHO/ISUPsystem classifies papillary urothelial carcinomainto only two
1grades®
1.2.9.1: Papillary urothelial carcinoma, Low grade:
Low-grade papillary urothelial carcinomahas an orderly appearance with
minimal architectural variability and/or cytological changes which are easily
discernable at low magnification (Figure 1.15). The significantfindings
include variations in nuclear size, shape, polarity and chromatin texture.
Mitotic figures are infrequent and usually seen in the lowerhalf of the
urothelium. The difficulty in differentiating papillary neoplasms of low
malignantpotential from papillary carcinomaof low grade is significant as
the histological differences maybe subtle. However, somecells within
papillary low grade carcinomaare overtly neoplastic, whereascells in
tumours of low malignant potential lesions show in general only nuclear
enlargement. Low grade papillary carcinomas may invade the lamina
propria, and have a low (<5%)risk of further progression but can frequently
recur’,
In the presence of low grade urothelial carcinoma, it is important to
understand that a variable spectrum of the histological patterns could be
present concurrently. The tumour should be graded based on the highest
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grade present. However,the currentpractice is to disregard minute areas of
highest-grade tumour. Thesignificance of this tendency on disease
prognosis has yet to be elucidated.
1.2.9.2: Papillary urothelial carcinoma, High grade:
High-grade papillary urothelial carcinomais an aggressive tumour with
markedarchitectural and cellular asymmetry. The cells appear irregularly
clustered with disorganised epithelium and a spectrum of cytological
pleomorphism. The nuclear chromatin tends to be clumped and nucleoli
may be prominent. Mitotic figures, including atypical forms, are frequently
seen at all levels of the urothelium (Figure 1.16). The consensusreport
suggested that instead of sub-classifying based on the variable level of
cytologic atypia, it would be an option for pathologists to comment onthe
degree of nuclear anaplasia. Moderate to marked nuclear pleomorphism,
abnormal mitotic figures, clumped chromatin and nucleolar prominenceall
favour high-grade over low-grade carcinoma.
There is a higherrisk of progression with high grade papillary urothelial
carcinomas varying from 15% to 40%'°. These tumoursalso have a high
risk of association with invasive diseaseat the time of presentation”®*”, In
equivalence to the high grade cytologic atypia within these lesions, the
surroundingflat urothelial mucosa may also demonstrate CIS.
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Figure 1.15: Low grade papillary urothelial carcinoma. Low magnification-
slight but definite nuclear pleomorphism with scattered hyperchromatic and
enlarged nuclei (arrows) relative to surrounding nuclei
 
Figure 1.16:High-grade papillary urothelial carcinoma with marked
architectural disorder
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1.3: Invasive Urothelial Neoplasia:
The descriptive nomenclature regarding invasive disease has also been
confusing. The importance of quantifying depth of invasion in planning
treatment and prognostic significance resulted in the WHO/ISUP committee
developing several recommendationsto provideclinicians with clear-cut
essential information.
1.3.1: pT; tumours:
The 2002 TNM (Tumour, Lymph nodesand Metastases) staging system
(Figure 1.17) defines pT; tumoursas those invading the lamina propriae
whichis the connective tissue layer underneath the mucosa. There may also
be an interrupted layer of smooth muscle (muscularis mucosae)*”. Invasion
of the lamina propria is characterised by urothelial cellular nests which have
breachedthe epithelial basement membrane. Another feature of invasive
tumourthat is not always present is an associated desmoplastic or
inflammatory stromal response.
There is a significant observervariability in diagnosing pTdisease with
concurrence varying from 61%-88% 3334 Kirkali et al. ° reported that
experienced genitourinary pathologists down-staged 56% of the tumours to
pTa on review, and up-staged 13% to muscle invasive disease. Downstaged
tumours showedless degree of progression than pT; tumours (17% vs 25%)
with consequent prognostic implications’.
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Key: Ta-Non-invasive confined to urothelium; T,-invades laminapropria;
T»-invades bladder muscle; T3-invades extravesicalfat;
T,-invades pelvic/abdominal wall/neighbour organs
Figure 1.17: Correlation of the extent of tumor invasion with the TNM
staging system of carcinomaofurinary bladder
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With extension of invasion, the cancer cells may exhibit eosinophilic
cytoplasm at the advancing edgeofthe infiltrating clusters and eventually
invades the smooth muscle bundlesof the detrusor. The important
discriminator remainsthe differentiation between invasion of the muscularis
mucosae and the muscularis propria as this has treatment planning
implications.
1.3.2: pT, tumours:
The urinary bladder muscle (detrusor) wall contains larger muscle bundles
referred to as the muscularis propria. Muscularis propria invasion (pT2)is
diagnosed when tumouris seen infiltrating thick smooth muscle bundles.
The depth of invasion can be difficult to appreciate especially in resection
specimen. This includes cases where there is extensive tumour with
scattered slips of muscle could give the appearance of muscularis mucosae
or could be markedly distorted and disrupted muscularis propriae. Also,
there are occasions when adequacy of muscle in the specimenis contentious
requiring a restaging resection.
The TNMstaging sub-classifies pT2 into pT2a; cancer invading <50% ofthe
muscularis propriae depth and pT2b where cancer invades more than % of
the muscularis mucosae. Theclinical benefit of this sub classification has
been questioned as studies have shownnosurvival difference”.
Roehrborn etal. *° (65% for pT2a, 61% for pT2b) and Pollacket al. *’ (78%
for pT2a, 77% for pT2b) reported similar 5-year survival in the two groups.
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Cheng et al.*° in a multivariate analysis reported that tumoursize rather than
depth was predictive of distant metastasis-free and cancer-specific survival
in patients with muscularis propriae involved cancer.
1.3.3: Extravesical disease:
pT3 & pT, tumoursrefer to extravesical (locally advanced) disease with pT3
denoting peri-vesical disease (a-microscopic, b-macroscopic) and pT4
denoting tumourthat has invaded other organs suchasthe prostate, uterus,
vagina, pelvic wall or abdominal wall.
The WHO/ISUPconsensusclassification is a nomenclature system for
urothelial lesions that can be understood by multi-disciplinary clinicians.It
has been an attemptto produceclarity in the staging so as to improve the
prognostic predictability as well as the treatment plan. Over a period of
time, this system islikely to be refined andrevised.
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1.4: Risk Factors:
There has been an improvementin survivalrates in patients with urothelial
carcinoma. Despite this, the socioeconomic burden remains high with the
total cost of bladder cancerestimated at £55 million between 2001 and
2002; almost 60% of which wasassociated with non-muscle invasive
urothelial cancer®®. Sangar et al.*® postulated the reasonsfor this high cost
of non-muscle invasive urothelial cancer (£8350 per patient) on incidence,
long survival requiring life-long follow-up and the frequent recurrences
requiring repeated resections and treatment. Grasso has suggested
implementing various strategies to reduce the burden of bladder cancer.
Prevention whereby occupational risk factors need to be understood and
protocols developed to modify/ reduce exposure risk. Early and accurate
diagnosis with the help of advanced techniques to stage bladder cancer more
precisely enables early intervention in patients before non-muscle invasive
urothelial cancer progresses to an aggressive andlife-threatening disease.
1.4.1: Smoking
Cigarette smokingis the most important modifiable risk factor for urinary
bladder carcinoma. The extent to which smoking can be held accountable of
developing bladdercanceris variable. There has been a worldwide
paradigm shift in bladder cancerincidence with a decrease in incidence and
mortality in western communities over the last few decades associated with
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a decline in smoking prevalence in both men and women.Thereis also a
shift in the tobacco epidemic towards the developing world with the WHO
reporting an increase of up to 16% in these countries*’. The most important
risk factor in present day population based studies is tobacco smoking.
Gandiniet al.“° in their meta-analysis estimated an on overallrelative risk of
urothelial cancer between current and former smokers of 2.77 and 1.72,
respectively. In Europe, an estimated 7/3" of cases in men and '/3"ofthe
cases in womenare attributable to smoking as a contributory cause"!
Brennanetal.” ina pooled European wide study suggest that there is an
increase in bladder cancerrisk linearly with duration of smoking. This crests
at an average of 15-20 cigarettes a day. There are several suggested
explanations for this threshold effect with numberof cigarettes and risk for
bladder cancer. Reports suggest that high volume smokers (>20
cigarettes/day) inhale less with individual cigarettes’ . The metabolic
polymorphismsalso involved may exert more prominenteffect at low levels
of exposure™*. However,these reports are in contrast to the morestriking
association of smoking with lung cancer where epidemiological studies have
failed to show an association with numberof cigarettes smoked but with a
greater than linear increase with smoking duration®’ which suggestthat the
group of carcinogens maybedifferent in these two disease groups. Tobacco
consumption maybe involvedin an early irreversible stage in the
carcinogenic processbased on the observationof a higher risk among long-
term smokers (>25years); also the tobacco consumption amountrather than
numberofcigarettes could bethe critical factor’”. This is corroborated by
studies which report very high adjusted odds ofgreater than five in black
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4 . . . .tobacco smokers*°. Black tobacco is suspected to be twice as carcinogenic
“7 48 with experimental data finding more concentratedas blond tobacco
aromatic aminesandnitrosamines”’ as well as urinary mutagenicity and 4-
aminobipheny! hemoglobin adducts levels”’ higher in black tobacco
smokers. This could be the explanation for higher odds ratio for developing
bladder cancer in countries such as Italy and Spain*’ in comparison with the
U.K. and U.S.A.
1.4.1.1: Marijuana:
Marijuanause hasseen rise in the 80s and 90s with stable rate of 4%
overthe last decade”. There has beena significant increase in dependence
and marijuana-related disorders in the last few years”*. This has been
attributed to the delta-9-tetrahydrocannabinol (THC)in marijuana”° which
has tumour promoting properties’. THClevels in the urine havea half-life
of almost three days compared to 12 hours for nicotine metabolites making
it a more potent stimulant of urothelial malignant transformation™ *°.
Marijuana also induces cytochrome P450 enzyme pathways which
potentiatesthe deleterious effects of nitrosamines and aromatic
hydrocarbons from tobacco smoking” 8
1.4.1.2: Passive smoke exposure:
This is a difficult entity to quantify. Zeegersetal.» in a large prospective
cohort study, found no significant association between secondhand smoking
a2
and an increased bladder cancer risk. However, there are other studies which
1.°° in a prospectivehave suggested a significant involvement. Alberg et a
cohort study with over 40 years follow up showeda 2.3 times increase in
bladder cancer risk in women exposed to secondhand smoke in comparison
to those not exposed with some reporting a dose responseeffect for the
amountof secondhand smoke exposed", Childhood exposure to smokealso
increased the risk of developing bladder cancer as an adult. Others feel
that the exposuresin utero and through mother’s milk which have higher
levels of nicotine in smoker mothers maybe responsible™ .
1.4.1.3: Cessation of smoking:
The risk of developing bladder cancer in former smokers decreases
dramatically with reduction of 40% within 1-4 years after cessation*” with
the risk reduction improving with the numberof years following cessation’.
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1.4.2: Occupational Risk:
Almost fifth of bladder cancers can be directly attributed to be
occupational exposure™, Occupational risk has been observedin the
occurrence of bladder cancersince the early 80s when the increased
incidence of bladder Ca wasnoted in the Yorkshirebelt. Boyko™ analysed
data from a large case control study on chemical dye workers in West
Yorkshire reporting 2-3 times increased risk in those exposedto aryl-
amines. Dose-responserelationship for calendar years of exposure
demonstrated a significantly increased risk in those exposed for over 30
years. B-naphthylamine and benzidine were banned in the United Kingdom
about 1950 and 1962, respectively. This along with 4- aminobiphenyl are
the main agents that have been associated with bladder cancer with high
relative risks. In the UK, revised workingpractices in place after 1960
have helped reducetherisk.
Oneof the major studies in assessing the occupational risk for developing
bladder cancer waspublished in the Journal of the National CancerInstitute
1.°’. They reported on the whole life occupationalin 1970 by Anthony et a
history of more than a thousand patients with bladder cancer in the Leeds
area. This was a case controlled study matched for age, sex, habitat and
smoking habits. Results confirmed the risk to dye workers and revealed
risks to medical workers (mainly nurses), to tailors, tailors' pressers, and
somegroupsof engineers and textile workers (associated with long-term
employmentonly), and possibly also to hairdressers andtailors’ cutters.
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Tumouroccurred at younger ages in men whohad been employedas dye
workers,tailors' cutters (P = < 0.025), or hairdressers (not significant)”.
This has been confirmed by other studies with reports of an increased odds
ratio for developing urothelial cancer in people dying cloth or dye
68 69manufacturing’, tailors®® with a positive trend with increasing duration of
employment”.
Studies including a meta-analysis’ have shownan increasedrisk in
painters® with benzidine based azodyes, one of the important carcinogenic
risk factors’* which may release aromatic amines in humans”* , leather
workers, shoe makers and in the rubbertyre industry’! ™.
A Canadian study® on risk of bladder cancer in men employed for more
than six months in the chemical industry have reported increasedrisk in
those exposedto dieselortraffic fumes anddrill press workers. Polycyclic
aromatic hydrocarbons (PAH), a product of petroleum combustion could be
responsible for a higher incidence reported in those workingin the
petrochemical industry, blacksmiths & mechanics’°; those exposedto oil,
gasoline, chemical materials, kerosene and asphalt.
However, despite paint and ink being linked solvents, no studies have
showna significant association with urinary bladder carcinomaalthough the
difficulty mightlie in the diverse nature of these occupations with variable
1677exposure ""’.
35
Aluminium smelting (Soderberg process)’® , coal mining or exposureto tar,
pitch or asphalt are other settings where significantly raised risks of
developing urothelial cancer have been reported with exposure to PAH”.
PAHconsist of fused aromatic rings, and being lipophilic are metabolised in
the liver by the cytochrome P450 system”. Various PAHs;if not rendered
labile can form PAH-DNAadducts which can lead to mutations in DNA
during cell division, resulting in mutations and consequentcarcinogenesisif
this occursin critical genes*’,
Another occupational group that has been studied are the agricultural and
horticultural workers. This was pertinent due to their increased exposure to
pesticides and weedicides. This group included workers involved in
pesticide manufacture and crop sprayers. Studies have suggested that there
maybe an increased risk*! but this has not been substantiated’®.
Health workers especially nurses have been reported to have an increased
risk. Most studies’’ ** have failed to show anassociatedrisk in either sex,
except a case series*’ were non-smoking male physicians were foundto
have a nine- fold relative risk.
Hairdressers, barbers, tailors and weavers have received extensive attention
especially in light of the evidence concerning synthetic dyes. Only Kabatet
al. (cohort study) have reported an increased risk for urothelial cancer*’,
Howeverconfounding factors such as smoking were not taken into account.
Exposureto synthetic materials for >10 years and launderers have been
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reported to have a higher risk of urothelial cancer of up to two times or
more. This is explained by exposure to dyes and synthetic materials.
Domestic helpers and Cleaners are alsoin this category.
In summary, employmentstudies convey an increased risk for urothelial
cancerin professions involved in manufacturing or using dyesorrelated
solvents. PAH has been reported to be the main culprit in the increased
noticed risk in people involved directly or indirectly with the petrochemical
industry. Most other occupations do not appear to be associated with an
increased risk towards developing bladder cancer.
1.4.3: Food and Beverages:
Theeffect of dietary parameters in cancerrisk has been long debated. Very
few studies have reviewedthe role of diet in urothelial cancer. A case-
control study from Uruguay assessed a variety of food sources reporting
significantly elevated risks with salted and barbecued meatas well asfatty
foods. Salted meat contained high levels of sodium chloride which has
previously been reported to be a carcinogen*’, barbecued meatcontaining
heterocyclic amines; another powerful carcinogen®’, Frequent consumption
of canned foodsattributable to the loss of vitamins in the canning process*®
and fried foods*® werealso implicated.
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Anti-tumoureffects have been reported with the ingestion of various food
items. There wasa significant protective effect with cooked vegetables,
citrus fruits, potatoes andall tubers®*. Cruciferous vegetables (cauliflower
and cabbage) have been found to have a high isothiocyanate levels which
have a chemo-preventive role in bladder cancer®”. Green vegetables and
carrots seem to offer protection with Wakai et al.” suggesting that a high
intake of green-yellow vegetables could decrease the bladder cancer
incidence by almost 40%.
1.88 in a matchedBeveragesintake has been difficult to quantify. Claude et a
case-control study of over 450 patients report their results on a range of
fluids. A significant oddsratio for drinking more than fourcups of coffee
daily of 1.3 was found. However, this association wasnot seen in non-
smokers. Beer consumption of more than one imperialpint a day increased
relative risk two fold after controlling for smoking*®*'. Howeverothers have
not found any association with coffee or high-proof spirits’. This could
be explained by the varying control groups and the different spirits
consumed. Patients with excessive alcohol intake might also have
nutritional deficiencies which maybe contributory. This corroborates the
findings from the Danish micronutrient intake study” from which dietary
beta-carotene (precursor of Vitamin A) have been shownto be associated
with a 18% lowerrisk per 500microgram higherintake. This vitamin A
precursorpotentiatesdietary anti-oxidative factors which maybe the true
effect modifiers. A large prospective Swedish study on high intake of
cultured milk suggest that >two servings of cultured milk was associated
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with a 38% lowerrisk”’. Others have reported decreased risk with
consumption of fermented milk products and yoghurt” °8Lactic acid
bacteria is considered the modulating factor by an unclear mechanism on the
immune system” and also suppressing food-derived urinary mutagenicity in
100humans. A Japanese cohort study of people who consumed milk on a
daily basis had a significant (53%) lower mortality due to bladder cancer’?!
with inconsistent evidence from other cohort studies071,
Urothelial carcinomais a multifactorial disease with both environmental
(and occupational) dietary and genetic factors involved in the development
and progression of this disease. However, the reportedstudies of
carcinogenic activity of various environmental carcinogens have provided
insubstantial or weak evidence precluding any strong suggestion that risk
modification would enable a reduction in incidence. This hasresulted in
researchers reviewing the genetic epidemiology of urothelial cancer.
Genetic variants in nucleotide excision and double strand break DNArepair
pathways and moderntissue microarray studies support the concept of
molecularalterations affecting “genetic pathways” leading to carcinoma.
Phenotypic and genotypic profiling of urothelial tumours have becomea
powerful approachthat provides valuable information on the biological
status of individual bladder cancers whichis detailed in the next chapter.
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Chapter2:
Phenotypic and genotypic pattern in
Human Urinary Bladder Carcinoma
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In the United Kingdom,transitional cell carcinoma(urothelial carcinoma)is
the most commontypeof urinary bladder carcinoma accounting for 90% of
the 10,091 bladder cancer cases diagnosed in 2007!°°. These cancers
becomeclinically apparentas either papillary lesions, whichare less likely
to invade rapidly or deeply into the bladder wall but have a high tendency to
recur necessitating multiple tumourresections; or the less commonflat
lesions which directly invade the bladder wall and are related to poor
prognosis’. Presently, the papillary tumoursare classified into three
morphological grades (UICCcriteria) accordingto their architectural
pattern, nuclear pleomorphism and mitotic figures. In contrast,
morphologically flat lesions could be either reactive, dysplastic or
neoplastic. Reactive lesions may contain inflammatory changesin the
lamina propria beneath a hyperplastic or metaplastic urothelium.
Cytological abnormalities occur in dysplasia and include cellular and
nuclear pleomorphismrestricted to the basal and intermediate layers.
Urothelial carcinomain situ (CIS) is frequently multifocal and characterised
by a flat proliferation of disordered urothelial cells with marked atypia. Flat
malignantlesions tend to be invasive and aggressive with a poorclinical
outcome(Figure 2.1).
Followinginitiation of these different morphological types of urothelial
neoplasmsby changes within distinct spectra of genes, the genotypic and
phenotypic factors which, thereafter, promote invasion and metastasis of
individual bladder cancersare likely to be similar.
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Figure 2.1 — Initial concept of the relationship between the origins of
superficial and invasive tumours.
Invasive transitional cell carcinomas can arise de novo'®’, occur following
8 or develop from the progression of aprogression of a flat lesion!
superficial papillary tumour”’ !°’, Nevertheless,identification of the invasive
potential of particular papillary or flat lesions remains a dilemma,
particularly in the pre-invasive stage. Morphologic similarities between
superficially-invasive papillary tumours that are recurrence-prone and
invasive tumours with deep bladder wall penetration presently confound
diagnostic and prognostic prediction. Although genetically encoded, many
of the factors that control the behavioural phenotype of an individual cancer
are likely to be epigenetic.
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Manystudies have been conductedto identify genes associated with bladder
111 112cancer development''®. Several molecular studies of transitional cell
bladder tumours have revealed characteristic chromosomal abnormalities.
1.''' proposed two distinct molecular pathways for bladderSpruck et a
cancer development with acquisition of particular chromosomal defects
responsible for invasive capability. The genes considered permissive for
malignant transformation comprised several oncogenes and tumour
suppressor genes.Initially quiescent, proto-oncogenes maybe activated by
critical genetic events which can include mutation, altered expression due to
hypermethylation or novelinsertion of viral DNA. Such events could occur
in isolation or following inactivation of a tumour suppressor gene, thus
causing a disturbance in the cell-cycle leading to malignant
: 11transformation!!°,
Two major chromosomesinvolved in bladder cancer, of both squamous and
papillary types, are chromosomes 9 and 17'3 ''4 Loss of heterozygosity
(LOH) on chromosome 9, characterize 60-65% of transitional cell
carcinomasandis considered by someto bethe earliest event in the genesis
of transitional cell bladder cancer''? ''*. Functional assays of transitional
assays have demonstrated lack of protein expression of cells containing
mutations of the pl6 gene’ or on the short arm (region p21) of
chromosome 9'!°. A high frequencyof allelic loss on chromosome 9p21
a Damageappears to be frequently involved in bladder cancer progression
to chromosome17 is suggested to be a late event. LOH of chromosome 17
short arm was noted in 40% of bladder tumours, mainly of high grade and
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high stage'!®, Tumours found to penetrate into muscle and beyond the
bladder wall contain losses on chromosomes 3, 4, 5, 6, 8, 11, 13 and 18.
Halachmiet al.'!? has compared the probable (suggested) genetic events
with pathological stage and has proposed a unified genetic pathway of
bladder cancer progression (Figure 2.2).
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Figure 2.2 — Proposed association between progression of genetic events
and evolution of the aggressive phenotype of bladder neoplasms
According to current understanding, mutations of tumor suppressor genes
(e.g. p16, p53, pRb and PTEN) diminish control of proliferation and are
permissive for accelerated growth. Thus, the dynamic equilibrium between
cell proliferation and apoptosis becomesdisturbed following deregulation of
the cell-cycle, allowing events favouring tumourigenesis to dominate. The
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rate of cell proliferation is an important factor contributingto initiation of a
malignancy. Expression of Ki-67 protein is a widely accepted measure of
this activity'°°. Apoptosis (programmed cell death) and regulation of cell
division is recognized to be controlled by a number of proteins including
Bcl-2, Bcl-X (L and S forms), Bax, Bad and Noxa, amongstothers. In their
non-mutated forms, tumour suppressor genes such as p53 and pRbinhibit
cell proliferation and repress factors that might otherwise stimulate tumor
development. Thereafter, malignancy is exploited by changes in cell-cell
and cell-matrix adhesions of isoforms of CD44 and undetected by the
reduced frequency of MHC antigens.
The genes currently considered to be some of the most important in the
etiopathogenesis of bladder cancer, particularly those of transitional cell
type, will be assessed in the remainder of this chapter. Wherever possible,
their practical diagnostic utility, and limitations, are discussed and
illustrated. While yet highly fragmented, a picture is now appearing of these
genes, their complexity and their interactions, that promote and modulate
individual malignant urothelial phenotypes, although the events initiating
involvementof these genes remain stubbornly obscure.
2.2: Alterations in Gene Expression and Activity
Investigations to try to elucidate the early changes in bladder cancer and to
understand the fundamental processes underlying the transition from initial
genetic changes to invasion and metastasis has been a complex process.
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Initial thoughts on the genetic pathways involved in bladder cancer were
based largely on chromosomal (cytogenetic) mechanismssuch as deletion or
duplication of entire chromosome arms, or even whole chromosomes. The
key events detected by this process showed the importanceofthe loss of the
short arm of chromosome9 (9p) and the subsequentloss of the short arm of
chromosome17 (17p). It is now knownthat the tumour suppressor gene p16
is located on chromosome 9p and p53 another key tumour suppressor is on
chromosome 17p. Gains or amplification of chromosomal regions were
associated with oncogene amplification such as that of the Ras genes. More
recent knowledge of gene structure and function, gene mapping and
sequencing culminating in the Human Genome Project has given much
greater insights into the genetic changes that underlie tumour progression.It
is now known that although chromosome loss is still one of the major
components contributing to loss of function of tumour suppressor genes,
there are other mechanisms that can contribute to loss (or gain) of function
of genes that play critical roles in oncogenesis. It is now recognised that
gene deletion or amplification may involve small microscopic deletions that
are difficult to detect at the gross chromosomal level unless specific gene
probes are used (examples of this are the tumour suppressor genes and
HER2/neu). Genes may be inactivated or changed by mutation. Even single
base changes can affect gene function, through mechanisms such as
producing a stop codon, thus initiating premature termination of the
messenger RNA produced or by affecting splice sites and thus splice
variants. Genes can also be silenced by methylation, or their function altered
by translocation so they are adjacent to other genes and control systemsthat
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mayresult in their under or overproduction(this latter processis particularly
important in the amplification of oncogenes). It is for these reasons that
more detailed information about some of the major genes involved in
bladder cancer progression aids understanding of the most fundamental
processesat each stage of progression. From this, pathways of the processes
underlying the major transitions in bladder cancer pathology have evolved
from those of basic mechanismsutilising chromosomal changes alone, to
those involving this rapidly expanding molecular genetic knowledge.
2.3: TUMOR SUPPRESSOR GENES
2.3.1: Gene: CDKN2A(Protein: p16)
Gene CDKN72A,also known P16, MTS1, TP16, CDKN2 or INK4a, maps
on chromosome 9, at 9p21. The products of these genes localize in the
nucleus where they have cyclin-dependent protein kinase inhibitor, tumor
suppressor activities and are involved in cell-cycle arrest, cell-cycle check
point, negative regulation of cell proliferation, regulation of CDK activity
and oncogenesis functions.
The gene generates several transcript variants which differ in their first
exons and utilize alternate polyadenylation sites. Its sequence produces, by
alternative splicing, 12 different transcripts together encoding 11 different
protein isoforms. There are seven likely alternative promotors and three
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non-overlapping alternative last exons. Four alternatively spliced variants
encoding distinct proteins have been reported, three of which encode
structurally related isoforms known to function as inhibitors of CDK4
kinase. The remaining transcript includes an alternate first exon located
upstream of the remainder of the gene and contains an alternate open
reading frame (ARF)that specifies a protein which is structurally unrelated
to the products of the other variants. This ARF product functions to stabilize
p53 protein andis able to interact with, protein MDM1responsible for p53
degradation. Although there are significant structural and functional
differences, the CDK inhibitor isoforms and the ARF product encoded by
this gene, are commonly involved in cell-cycle control at G1 through
regulation of the activities of CDK4 and p53. This gene is frequently
mutated or deleted in a wide variety of tumors, including bladder cancer,
and is recognised to be an important tumor suppressor gene.
2.3.2: Gene: WAF1/CIP1 (Protein: p21)
The gene encoding protein CDKNIA is known as p21, CIPI, WAFI or
CDKNI1and mapson chromosome6,at 6p21. The products localize in the
nucleus and have potent cyclin-dependent protein kinase inhibitor, cell-
cycle regulator activities involvedin cell-cycle arrest. The gene is expressed
at a very high level and produces, by alternative splicing, 13 different
transcripts altogether encoding 12 different protein isoforms. The encoded
protein binds to, and inhibits, the activity of cyclin-CDK2 or —-CDK4
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complexes, thus functioning as a regulator of cell-cycle progression at G}.
Expression of this gene is tightly controlled by tumor suppressor protein
p53, through which this protein mediates the p53-dependent cell-cycle G1
phasearrest in responseto a variety of stress stimuli. The WAF1/C1P1 gene
contains at least two p53-responsive sites in its promoter region, responsible
for transcription of p21 when bound to p53, thus suggesting protein p21 to
be a potent downstream mediator of the anti-proliferative function of wild-
type p53'7), Conversely, a p53-independent pathway has been associated
with p21 induction observed in various normal tissues during development
or differentiation, in the absence of p53 activation as well as in tumourcells
with mutated p53 cenee
Controversy persists concerning the prognostic utility of p21 expression in
bladder cancers. Maintenance of p21 has been suggested to reduce the
'22Conversely, an associated p53deleterious effects of altered p53 in TCC’s
mutation appears to enhance chemosensitivity'~ . An inverse correlation has
been suggested between p21/WAF1 immunoreactivity and tumour stage,
grade, p53 accumulation and Ki-67 expression in muscle invasive
tumours'*° '*”, However, the value of immunohistochemically-derived data
is now questionable (Figure 2.5). This study caveat applies not only to the
WAFI/CIP1 gene, but also to the products of other genes with multiple-
spliced products. Nevertheless, Quereshi et al. showed distinct prognostic
groups with p21+, p53+ tumors associated with the best survival advantage
and p21-, p53- tumors the worst'*®, Zlotta et al. reported increased p21
expression with the grade and stage of superficial tumors, attributing a
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lower recurrence-free survival and a positive correlation with p53 but not
with Ki-67'”. Studies of p21 immunoexpression by Waldman et. al.
reported better chemo-radiosensitivity in p21 negative bladder-cell lines
raising the possibility of an antiapoptotic function all
2.3.3: Gene: TP53 (Protein: p53)
Gene TP53, also known as p53 or TRP53, maps on chromosome 17, at
17p13.1. The gene product, tumour protein (Tp53) is a nuclear protein that
plays an essential role in regulating the cell-cycle, specifically during
transition from Go to Gy. In normalcells, it is found in very low levels but in
a variety of transformedcell lines it is expressed in high amounts, and is
believed to contribute to neoplastic transformation and to malignancy. Tp53
is a DNA-binding protein containing DNA-binding and transcription
activation domains. It is postulated that p53 activates expression of
downstream genesthat inhibit growth and/or invasion, thus functioning as a
tumour suppressor. Alterations of the TP53 gene occur not only as somatic
mutations in human malignancies, but also as germline mutations in some
cancer-prone families.
Protein p53 regulates progression through the cell-cycle in G; and G» in
response to DNA damage and to apoptosis which occurs following a range
of DNA damaging agents’ '. In non-transformed cells, p53 causes arrest
after G;, allowing time for cell repair or apoptosis. The gene is inactivated
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2.in up to 50% of all cancers including the bladder’ and is the most
frequently modified gene in bladdercancer.It is possibly the most important
ee Although many differentgene involved in the progression of this disease
mutations are recognized to occur within the genome, mutated p53 usually
differs by a single point mutation from the wild type resulting in an amino
acid substitution. All such mutations occurin areas of the gene conserved by
evolution. One particular region (‘hotspot’) comprises four codons in which
more than 30% of mutations are knownto occur. Inactivation of this gene
inhibits activity of the normal protein resulting in a proliferative advantage
to affected cells!*4, causing them to become unstable. The retarded
degradation and nuclear accumulation conferred upon abnormal p53
proteins is a reflection of elevated stability and self-aggregation of the
mutated molecules'*. Thus, mutant p53 products are more likely to be
detected using immunohistochemical analysis.
The TP53 gene has been studied in urothelial carcinoma with mutations
136 137 1correlating with grade and stage , recurrence’*®, progression'! , and
survival!*?. Dahse et al. found TP53 abnormalities to be more frequent in
high grade, muscle-invasive lesions and hypothesised that low grade bladder
TCC’s (Figure 2.4) proceed through another genomic pathway associated
with the inactivation of CDK inhibitors p15, p16 and p21 40" Sarkis et al.
showed significant decrease in the survival rate of patients with muscle-
invasive cancer and altered p53 function'*’. Bladder tumours with TP53
alterations exhibited more aggressive phenotypes and gene mutation rates
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correlated with higher grading and/or staging together with muscle
invasiveness!*”,
2.3.4: Gene: RB1 (Retinoblastoma protein: pRb)
The RB1 gene maps on chromosome 13, at 13q14.2 where it consists of 27
exons'“’.It encodesa retinoblastoma-associated protein that has tumour
suppressoractivity. The gene sequence produces,by alternative splicing, 11
different transcripts altogether encoding 10 different protein isoforms.
Retinoblastoma-like and retinoblastoma-associated proteins have regulatory
functions in cell-cycle. The proteins form a complex with adenovirus E1A
and SV40 large T antigen, and may bind and modulate the activities of
certain cellular proteins with which T and E1A compete for pocket binding.
These proteins mayalso act as tumour suppressors and are potent inhibitors
of E2F-mediated trans-activation. Retinoblastomaprotein regulates cell-
cycle progression accordingto its own state of phosphorylation which
reachesits peak at the beginning of S phase and is lowest after mitosis.
Retinoblastoma protein pRBis a target for the enzymatic activity of cyclin-
CDK complexes'“* 'Phosphorylation of pRB occursas cells progress
from G; through late G,, early S phase and Gp. The active
underphosphorylated form of pRB exerts a negative regulatory effect on
gene expression in Go to middle G; through complex formation with DNA-
binding proteins “°. Stimulation of quiescent cells with mitogens induces
phosphorylation of pRb, whereas differentiation of the samecells
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Figure 2.3: Heterogenous expression of p21 gene product by flat
urothelial lesion that is p53 mutation-positive and also PTEN
downregulated
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Figure 2.4: Early papillary urothelial carcinoma containing a p53 mutation.
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Figure 2.5: Early papillary urothelial carcinoma containing Rb mutation in
which the urothelial cells are morphologically unremarkable
 
Figure 2.6: Early papillary urothelial carcinoma-Rb & p53 positive
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induces hypophosphorylation. It is the hypophosphorylated form that
suppressescell proliferation'*”, Mutations to the Rb gene can occur through
a numberof different mechanisms, all causing inactivation of pRb. Large
scale deletions account for 30% of mutations, the remaining 70% being
caused by splicing errors, point mutations and small deletions in the
promoterregion.
Mutagenic deactivation of RB produces a spectrum of altered expression
patterns, from undetectable pRB levels (Figure 2.5) to heterogeneous
cytoplasmic localisation of truncated pRB products that have lost their
nuclear localisation signal'*® ‘49Thus, in any bladder carcinoma, the precise
levels of pRb are not static but are in constant flux (Figure 2.6).
Furthermore, these pRb proteins are subject to splice variation, making
single-agent detection highly unreliable. Cordon-Cardo et al. found
significant associations between undetectable pRB and tumorstage, grade,
1° Altered Rb expression,disease progression and reduced surviva
identified immunohistochemically, was associated with a high rate of
recurrence and poor outcomein T; tumours’. Mutated expression of the Rb
gene found in association with muscle invasive tumors suggests a functional
importance during acquisition of an invasive capability a
There is significant association between p53 nuclear over-expression and
undetectable pRB'”, including a synergistic carcinogenic effect between
mutated Rb and p53 such that patients with both alterations manifest an
advanced tumor grade, marked progression and decreased survival. TP53
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appears to target p21/WAF1, which encodes a CDK inhibitor'”'; pRBbeing
a substrate for cyclin-CDK complexes!“ 5.
2.3.5: Gene: PTEN
The gene PTENis also known as BZS, MHAM, TEP1, MMAC1or PTENI
maps on chromosome 10, at 10q23.3. Its sequence produces, by alternative
splicing, 9 different transcripts together encoding 9 different protein
isoforms. It encodes a phosphatase tensin homolog family member. The
products localize in cytoplasm, have tumor suppressor, protein tyrosine
phosphatase activities and are involved in regulation of CDK activity,
development, cell proliferations and protein amino acid dephosphorylation.
PTENis a major tumour suppressor gene frequently mutated or deleted in a
wide range of tumours. It encodes a dual-specific phosphatase which, when
non-mutated and active, can restrain the capacity of tumourcells to invade
through a basement membrane matrix (Figure 2.7). PTEN over expression
leads to changes in cell adhesion, spreading and inhibits cell migration’.
Studies have found involvement of PTEN protein in the regulation of cell
migration and invasion with its loss being significant in late stages of
'S3 154 The response of PTEN in bladder neoplasiaistumour progression
complex and its role remains to be elucidated in individual cancers.
Immunohistochemical studies confirm the protein to be modulated in an
individual and idiosyncratic manner. In non neoplastic transitional
epithelium, PTENis strongly expressed by manybasalcells.
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Figure 2.7: Early papillary urothelial carcinoma-strongly PTENpositive
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Figure 2.8: Early flat neoplasia-PTEN negative; p21 positive
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However, in some neoplasms, early PTEN expression becomes diminished
(Figure 2.8) only to recur at high intensity as the tumour becomesinvasive.
Unfortunately, immunohistochemistry is insufficiently sensitive to
discriminate whether there is a quantitative or qualitative change in
expression of the productsof this gene.
2.4: ONCOGENES
Oncogenic gene sequences encode proteins that have normal function and
are described as “proto-oncogenes”. However, when the gene is mutated
(“oncogene”), the abnormal protein product becomesa strong independent
oncogenic stimulus that operates outwith normal cellular regulatory
mechanisms.
2.4.1: RAS genes
The ras gene maps on the X chromosome where it encodes ras-related
protein Rab-6B.It is expressed at low level in normal cells and producesby,
alternative splicing, two different transcripts together encoding two different
protein isoforms. There are two probable alternative promoters. The
transcripts appear to differ by truncation of the N-terminus, because an
internal intron is not always spliced-out.
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The ras branch of the ras super family consists of small GTPases most
closely related to ras and include the r-ras, Rap, Ral, Rheb, Rin and Rit
proteins. Although understanding ras signalling and biology is now
considerable, recent observations suggest that the function of these proteins
is more complex than previous believed. First, the different ras proteins may
not be functionally identical. Second, ras protein function involves
interactive cross-talk with their close relatives.
The mammalian ras gene family consists of the Harvey and Kirsten ras
genes (c-Hras! and c-Kras2), an inactive pseudogene of each (c-Hras2 and
c-Kras1) and the N-ras gene. These proteins differ significantly only in their
C-terminal 40 amino acids. These ras genes have GTP/GDP binding and
GTPase activity, and their normal function may be as G-like regulatory
proteins involved in the normal control of cell growth. Point mutations in
the three membersof the RAS proto-oncogene family (H-ras, K-ras, N-ras)
are common in human cancers’ and suspected in the development and
progression of many human bladder cancers. A high incidence of both H-ras
and K-ras mutations at codon 12 have been reported in histochemically-
confirmed bladder cancers'” '*°. In these tumours, Przybojewska etal.
found frequent N-ras gene mutation at codon 61 associated with H-ras
mutations'”’. Fontanaet al. demonstrated a significant relationship between
enhanced c-ras oncogene expression and early recurrence in superficial
157bladder cancer'*’.
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2.4.1.1: Gene: H-RAS
The Harvey ras gene (H-RAS) also known as HRAS1 or RAS111, maps on
chromosome 11, at 11p15.5. The gene encodes transforming protein
products that have GTP binding properties, GTPase activities and are
involved in small GTPase-mediated signal transduction. The gene is
expressed at very high level and its sequence produces, by alternative
splicing, 9 different transcripts together encoding 5 different protein
isoforms.
2.4.1.2: Gene: K-RAS2
The Kirsten ras gene (K-RAS2) also known as RASK2, KI-RAS, C-K-RAS,
K-RAS2A or K-RAS2B, maps on chromosome 12, at 12p12.1. It encodes
transforming GTPase protein products that have GTPase activity and are
involved in small GTPase-mediated signal transduction. The gene sequence
produces, by alternative splicing, 3 different transcripts altogether encoding
3 different protein isoforms. Single amino acid substitutions are responsible
for activating mutations. Alternative splicing leads to variants encoding two
isoformsthat differ in the C-terminal region.
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2.4.1.3: Gene: N-RAS
The N-RASgene also knownas N-ras or NRAS1, maps on chromosome1,
at 1p13.2. It encodes transforming protein products predicted to have small
GTP binding ability and GTPase activities, and to be involved in small
GTPase-mediated signal transduction. Mutations which change amino acid
residues 12, 13 or 61 activate the potential of N-ras to transform cells in
tissue culture and are implicated in a variety of human tumours.
2.4.2: Gene: c-ERBB-2
ERBB2gene also known as NEU, NGL, HER2, TKR1 or HER-2, maps on
chromosome 17. at 17q21.1'* 'S° The protein productis a transmembrane
glycoprotein within the receptor protein-tyrosine kinase family’.
Specifically, the protein exhibits Neu/ErbB-2 receptoractivity in addition to
protein kinase, transmembrane receptor protein tyrosine kinase, epidermal
growth factor receptor and ATP binding activities. The protein products of
the gene localize in membrane and are involved in protein amino acid
phosphorylation and transmembrane receptor protein tyrosine kinase
signalling pathways. The gene sequence produces, by alternative splicing,
19 different transcripts, together encoding 19 different protein isoforms.
ErbB-2 (also known as HER-2/neu) is a proto-oncogene implicated in a
numberof tumors'®'. Some of these proto-oncogenesare related to growth
factors or to growth factor receptors (such as c-sis, c-fms, c-erbB-1 and c-
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erbB-2)'©'™, Over expression and amplification in bladder cancer (Figure
2.9) correlates with tumor grade, re-occurrence and disease progression'®
166 Several reports indicate a significant relationship between erbB-2, p53
167 168 with these oncoproteins rarelyand increased cell proliferation
‘ . 167 169-171 ;expressed in superficial tumors . ErbB-2 over expression appears to
precede disease progression suggesting prognostic value’,
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Figure 2.10: G3pT1 carcinoma- strongly expresses nuclear Ki-67 protein
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2.5: TUMOR MODULATING GENES
2.5.1: Protein: Ki-67
This is the product of gene MK167, also known as KIA, which maps on
chromosome10, at 10q25. It is expressed at very high levelin all cells. The
gene produces,byalternative splicing, three types oftranscripts predicted to
encode three distinct proteins. Protein Ki-67, detected by
immunohistochemically murine monoclonal antibody MCB1, is a good
indicator of proliferation in a variety of tumours, including bladder!” |”,
This proliferation-associated nuclear antigen is expressed in all cells in Gl,
S and G2M phases butnot by cells in GO, thus allowing assessment of the
1'’*. Ki-67 expression studies have shown aentire proliferating cell poo
strong overall correlation with tumour stage and grade'”° . High grade TCC’s
(Figure 2.10) tend to have a higher Ki-67 index than low-grade tumours,
although this is not a universal or invariable relationship. Studies have also
shown a correlation with tumour aggressiveness, both recurrence and
'76 and metastasis. Ki-67 index can helpprogression to invasive disease
distinguish Grade 2 tumours with a favourable outcome from clinically
unfavourable tumours of identical morphology'’’. A Ki-67 labelling index
over 20% predicts that morphologically well-differentiated tumours of
pathological stage pTa/pT, will recur within a year of diagnosis!”®,
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2.6: CYP2B6 encoding cytochrome P450
Gene CYP2B6, also known as CPB6, IIB1, P450, or CYPIIB6 maps on
chromosome 19, at 19q13.2. The gene encodes a member (P-450 2B-BX) of
the cytochrome P450 superfamily of enzymes, is moderately expressed and
produces 2 different protein isoforms by alternative splicing. There are 2
probable alternative promoters, although these have yet to be confirmed by
functional studies. The transcripts appear to differ by truncation of the N-
terminus, presence or absence of a cassette exon byalternative splicing the
gene produces 2 types of transcripts, predicted to encode 2 distinct proteins.
It contains 9 confirmed introns, 4 of which are alternative. The products are
involved in electron transport.
Cytochrome P450 proteins are monooxygenases which catalyze many
reactions involved in drug metabolism, in the synthesis of cholesterol,
steroids and other lipids, and hence are indirectly involved in maintaining
cellular homeostasis. This protein localizes to the endoplasmic reticulum
and its expression is induced by phenobarbital. The enzyme is known to
metabolize some xenobiotics, such as the anti-cancer drugs
cyclophosphamide and ifosphamide. Transcript variants for this gene have
been .described. However, it has not been confirmed whether these
transcripts are produced by this gene or by closely related pseudogene,
CYP2B7. Both the gene and the pseudogeneare located in the middle of a
CYP2A pseudogene found on chromosome 19q within a large cluster of
cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies.
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The cytochrome P450 motif is found in 2 isoforms from this gene. 62 other
genes in the database also contain this motif. The cytochrome P450
enzymes usually act as terminal oxidases in multicomponent electron
transfer chains. The significance of this observation is self-evident with
respect to the production of monoclonal antibodies to specific proteins and
to possible overlapping functions of apparently dissimilar proteins.
2.7: Gene: FGFR3 encodingfibroblast growth factor receptor 3
Gene FGFR3, also known as ACH, CEK2, JTK4 or HSFGFR3EX maps on
chromosome 4, at 4p16.3. It encodes a growth factor receptor with ATP
binding and protein kinase activities. It is involved in protein amino acid
phosphorylation. The gene is expressed at high level and produces, by
alternative splicing, 7 different transcripts altogether encoding 7 different
protein isoforms. There are 2 probable alternative promotors and 2 non
overlapping alternative last exons. The transcripts appear to differ by
truncation of the N-terminus, truncation of the C-terminus, presence or
absence of 4 cassette exons, common exons with different boundaries,
because an internal intron is not always spliced out.
The protein encoded by this gene is a member of the fibroblast growth
factor receptor family, where amino acid sequence is highly conserved
between members and throughout evolution. FGFR family members differ
from one another in their ligand affinities and tissue distribution. A full-
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length representative protein comprises an extracellular region containing
three immunoglobulin-like domains, a single hydrophobic membrane-
spanning segment and a cytoplasmic tyrosine kinase domain. The
extracellular portion of the protein interacts with fibroblast growth factors,
initiating a cascade of downstream signals, ultimately influencing
mitogenesis and differentiation. This particular family memberbindsacidic
and basic fibroblast growth hormone.
2.8.1: Gene: ESR1 encoding estrogen receptor 1 (ER alpha)
Gene ESR1, also known as ER, ESR, Era, ESRA or NR3A1 maps on
chromosome 6, at 6q25.1. It encodes an estrogen receptor localized in
nucleus with DNA binding, transcription factor, steroid hormone receptor
and steroid binding activities. The products are involved in the regulation of
transcription. Estrogen receptor (ESR) is a ligand-activated transcription
factor composed of several domainsthat are important for hormone binding,
DNAbinding, and activation of transcription. It is expressed at high level in
many cells and produces, by alternative splicing, 11 different transcripts
together encoding 11 different protein isoforms. There are 5 probable
alternative promoters and 5 non overlapping alternative last exons. The
transcripts appearto differ by truncation of the N-terminus, truncation ofthe
C-terminus, presence or absence of 5 cassette exons, common exons with
different boundaries.
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The ligand-binding domain of this nuclear hormone receptor motif is found
in 7 isoforms from this gene. At least 47 other genes are knownto contain
this motif. The steroid hormones and their receptors are involved in the
regulation of eukaryotic gene expression andaffect cellular proliferation and
differentiation in target tissues. In the absence of ligand, steroid hormone
receptors are thought to be weakly associated with nuclear components.
Hormonebinding greatly increases receptor affinity. The hormone-receptor
complex appears to recognize discrete DNA sequences upstream of
transcriptionalstart sites. The estrogen receptor motif is found in 5 isoforms
from this gene. No other gene in the database containsthis motif.
2.8.2: Gene ESR2 encoding estrogen receptor 2 (ER beta)
Gene ESR2, also known as Erb, ESRB, NR3A2, ER-BETA or ESR-BETA
maps on chromosome 14, at 14q. It encodes estrogen receptor beta that is
well expressed in many different cell types. The gene produces, by
alternative splicing, 9 types of transcripts, predicted to encode 7 distinct
protein isoforms. It contains 28 confirmed introns, 27 of which are
alternative. There are 6 probable alternative promotors and 4 non
overlapping alternative last exons. The transcripts appear to differ by
truncation of the N-terminus, truncation of the C-terminus, and the presence
or absence of 8 cassette exons. The products have a wide range of properties
including steroid binding, transcription co-activator, transcription factor,
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receptor antagonist, and estrogen receptor activities. The gene products are
involved in regulation of transcription, DNA-dependent, signal transduction,
cell-cell signalling, negative regulation of cell growth, estrogen receptor
signalling pathway and localize in the nucleus. Estrogen receptor-beta
(ESR2) is a member of the super family of nuclear receptors, which
transduce extracellular signals into transcriptional responses. The gene is
antisense to gene SYNE2. Thepossibility that its mRNAs may be present
and stable only in the absence of matching mRNAsfrom the gene on the
other strand and vice versais a distinct possibility.
2.9: Gene: Epidermal growth factor receptor (EGF-R)
The EGF-R gene, also known as ERBB or ERBB1, maps on chromosome7
at 7p12 and encodes an epidermal growth factor receptor with protein
kinase, transmembrane receptor protein tyrosine kinase and ATP binding
activities. The receptor is involved in protein amino acid phosphorylation,
transmembrane receptor protein tyrosine kinase signalling and localizes in
membrane. The gene is expressed at very high level and produces, by
alternative splicing, 10 different transcripts altogether encoding 10 different
protein isoforms. EGF-R is a 170 kDa protein product of a proto-oncogene
with three domains that are extracellular, transmembrane and intracellular.
Activation of EGF-R by ligands such as epidermal growth factor,
transforming growth factor-a, betacellulin and amphiregulin results in
stimulation of the ras/raf, phophatidylinositol-3-kinase and protein kinase C
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pathways culminating in increased nuclear transcription and cellular
- - 17 ‘ ‘ . .proliferation ” as well as increased angiogenesis and reducedapoptosis.
EGF-R immuno-expression, normally confined to the basal cell layer of
180 181 .80 181 is reported to be over-expressed in theurinary bladder epithelium
entire urothelium involved in bladder TCC'® !7! '®?"'®*, Over-expression of
EGF-Rcorrelates with a shorter interval to recurrence, higher recurrence
rate and an increasedrate of progression in patients with superficial bladder
cancer but not in patients with muscle invasive disease'*’. Its expression
suggests that the phenotype of an individual bladder cancerin notstatic but
evolves with the stage of disease progression. Stein et al.'® suggested that
increased expression of EGF-R in histologically normal urothelium or the
presence of high EGF-R levels in normal urothelium distant to a tumour
site'*! are early events in bladder tumourigenesis.
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2.10: Heat Shock Proteins
There are two known genesencoding homeostatic regulatory proteins in this
family: The gene known as HSPB1, also as HPS27, HSP28 or HSP25 maps
on chromosome7, at 7q11.23. The protein products have heat shock protein
activity and are involved in regulation of translational initiation and localize
in the cytoplasm. The gene is expressed at a very high level and produces,
by alternative splicing, 16 different transcripts altogether encoding 13
different protein isoforms. There are 2 probable alternative promoters.
The gene known as HSPB2 also as MKBP, HSP27, HSP72, HS.78846,
FLJ25219 or MGC14839 maps on chromosome 11, at 11q22-q23. The
products localize within the cytosol, have enzymeactivator, protein binding,
heat shock protein activities and are involved in response to cellular
“stress”. The gene is expressed at high level and produces, by alternative
splicing, 6 different transcripts altogether encoding 6 different protein
isoforms. Its regulation may use antisense and coregulation with
neighbouring genes organized in an operon-like structure.
Heat shock protein (hsp) modulation is an essential cellular defence
mechanism found in both prokaryotic and eukaryotic organisms as a
responseto a variety ofstress insults. Hsp-27, -60, -70 and —90, present in
all living cells, play key cytoprotective roles as molecular chaperones of
other proteins. They participate in developing cellular resistance and
intracellular protein stabilisation'®* '*’, By inhibiting apoptosome formation,
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hsp-70 inhibits the receptor or mitochondrial pathways hampering the
caspase cascade that leads to apoptosis'**. Hsp-70 interacts with p53
protein, stabilising the mutant form, thus permitting cell proliferation thatis
thereafter unregulated by this pathway”. Hsp’s act as antigen presenters
and play an important role in antibody assembly. Over expression of hsp’s
has been associated with poor prognosis but may increase immunogenecity
in some tumours, potentiating immune response and improved overall
survival'’°’. In superficial bladder cancers with a propensity to recur’,
studies have shown that hsp over-expression may be an important
prognosticator of BCG response. The universal expression of hsp-27 in
normal urothelium makes this a powerful immunohistochemical reagent
with which to detect early invasive disease (Figure 2.11). However, some
transitional cell carcinomas express hsp-27 only at very low level, although
immune-reactivity may be dependent upon the expression of individual
splice-variants and the reactivity of particular monoclonal antibodies with
these variants. Nevertheless, relative absence of this protein from these
tumors appears to be a strong (but hitherto unconfirmed) indicator of their
potential aggressiveness.
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 Figure 2.11: Small clusters of Invasive tumour within submucosa-strong
HSP-27 expression. Invaluable marker in discriminating pTa from pT1
Figure 2.12: Normalurothelium with bcl-2 positive in basal layer. Loss of
bcl-2 occurs early in neoplasia
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2.11: Apoptotic Modulators
2.11.1: Gene: Bcl-2
The chromosomal localization and sequence of the bcl-2 gene has not yet
been mapped. However, the principal product of the bcl-2 gene is a ~25-26
kDaintegral membrane protein, mainly located in the outer mitochondrial
membrane and to a lesser extent in the endoplasmic reticulum and nuclear
envelope. It is known that presence of the bcl-2 protein promotes cell
survival, even whentherate of cell proliferation is not high, thus providing
a growth advantage that eventually may lead to neoplastic transformation”.
This may be of particular importance in the normal bladder where the
proliferation index of normal urothelium is extremely low. Krajewski etal.
suspected bcl-2 to influence the activity of Ca**- dependant enzymes
involved in apoptosis by regulating the activity of Ca’* pumpsor channels
in the ER, mitochondrial and nuclear membranes'”’. Nakopoulou etal.
‘observed an increased bel-2 expression in low-grade TCC’s and in
superficial rather than invasive TCC’s. Conversely, high grade, aggressive
and advanced tumors tend to show non-basal bcl-2 over-expression’?'°®,
This finding suggested a deregulation of mechanisms controlling bcl-2
expression. Prognostic significance of bcl-2 expression is controversial with
Atug et al.'°° and Kirsh et al.'” concluding an unfavourable outcome,
1, '°8and Lipponenet al.'°’. The commonexpression ofrefuted by Li et a
bel-2 in normal (Figure 2.12) and dysplastic urothelium but its loss from
low grade TCCsuggeststhat bcl-2 expression may be an early event in TCC
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tumorigenesis”. Also, a reciprocal relationship between bcl-2 and p53 has
been reported with presence of p53 implying greater probability of
‘ » 202-205 . : : .invasion . These earlier findings are at some variance with respect to
current findings from this laboratory.
Apoptosis (programmedcell death) plays an importantrole in physiological
processes such as embryogenesis, organ developmentandcell proliferation.
It is also an important function in pathological processes including
autoimmune disease and cancer development”. Bcl-2 belongs to a family
containing both pro- and anti-apoptopic genes”””. Bcl-2 inhibits apoptosis
induced by a numberof stimuli such as radiation, chemotherapeutic agents
and growth factor deprivation. It is unusual in that its function assists
neoplastic growth by prolonging cell survival through inhibition of
apoptosis rather than accelerating cell proliferation, thus enhancing the
metastatic potential of a tumor””. Bcl-X,, from the same family, is also an
anti-apoptopic gene which displays distinct patterns of expression to Bcl-2
in TCC’s, suggesting that the two proteins regulate different cellular
functions at specific stages ofcell differentiation’”’.
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2.11.2: Gene: Bcl-X
This gene BCK2L1, also known as BCLX, BCL2L, Bcl-X, bel-xL, bel-xS
or BCL-XXL/S, maps on chromosome20, at 20q11.21. The gene sequence
produces, by alternative splicing, 21 different transcripts altogether
encoding 9 different protein isoforms. There are 4 probable alternative
promoters. The transcripts appear to differ by truncation of the N-terminus,
presence or absence of 3 cassette exons, common exons with different
boundaries. As a result of alternate splicing the gene encodes two
functionally different proteins. The longer Bcl-X, is anti-apoptopic while
the shorter Bcl-Xsg facilitates apoptosis by interfering with the action of Bcl-
219° 207 208 The proteins encoded by this gene are located at the outer
mitochondrial membrane, and have been shown to regulate outer
mitochondrial membrane channel (VDAC) opening. VDAC regulates
mitochondrial membrane potential, and thus controls the production of
reactive oxygen species and release of cytochrome C by mitochondria, both
of which are the potent inducers of cell apoptosis. Two alternatively spliced
transcript variants, which encode distinct isoforms, have been reported.
These homologuesof the bcl-2 gene family have been demonstrated to show
a high degree of over expression in TCC but only moderately in normal
urothelium?”’, Kirsh et al. found that immunohistochemical staining of
bladder cancercell lines reflected a comparatively higher Bcl-X, expression
than Bcl-X,!””.
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In this laboratory, evidence from immunohistochemical studies is at
variance with some findings reported elsewhere. Previously, strong
expression of Bcl-2 in the basal cells of normal transitional epithelium
(Figure 2.12) becomes attenuated as an early event in bladder neoplasia,
even when the architecture is not overtly dysplastic. Surprisingly,
expression of this protein occurs infrequently in established bladder cancers
— whetherin situ or invasive. This consistent lack of immunohistochemical
staining may be due to a numberoffactors including the specificity of the
particular antibody employed and possible splice-variants of the proteins
expressed in bladder neoplasia. Nevertheless, there is a distinct reciprocal
correlation between diminished expression of Bcl-2 and enhanced
expression of HER2/neu suggesting that the observed loss of identified
splice-variant of the protein is a real phenomenon.
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2.12: Gene: CD44 ADHESION MOLECULE
Gene CD44, also known as IN, MC56, MDU2, MDU3, MIC3, Pgp1 or
CD44R, maps on chromosome 11, at 11p13 and contains at least 20
exons!771°. Tt encodes cell surface glycoprotein CD44 that has collagen
binding, hyaluronic acid binding and cell adhesion receptor activities. The
gene is expressed at very high level and its sequence produces, by
alternative splicing, 21 different transcripts altogether encoding 21 different
protein isoforms.
The term “CD44” refers to a family of widely distributed cell surface
(cluster differentiation) glycoproteins with an array of functions and many
isoforms. The inappropriate and overabundant expression of this gene is of
210 211 as wellpotential value in tumor diagnosis and in prognostic evaluation
as in further understanding of adhesion aspects of tumor biology. A
correlation has been identified in the altered quantity and distribution of
CD44 variant isoforms (CD44v) and in the progression of a number of
different tumours”'”. CD44v6 isoform expression is reduced in poorly
differentiated, invasive urothelial cancer cell lines when compared to well-
or moderately-differentiated non-invasive tumors”!**!°, In bladder cancerit
has been reported that overexpression of the CD44 locus is seen early in
malignancy, this progressively diminishes as the tumor invades deeperinto
the bladder wall and is linked to loss of function of cell-cell cohesion,
detachment of the basement membrane andinfiltration of the surrounding
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muscle. The pattern of CD44 expression confirms that the environment
surrounding a tumorcell affects its regulation 106.
Correlation between CD44 expression and prognosis has been reported with
strong expression related to high survival probability in muscle invasive
tumors”!*. Toma et al. found that focal loss of immunostaining against
CD44v3 and -v6 was a significant factor in identifying patients with non-
muscle invasive urothelial carcinomaat high risk of recurrence”'°. Suginoet
al. found that detection of CD44 overexpression wasof importance not only
in detecting early bladder cancerbut also in evaluating borderline lesions!”.
2.13: Gene: Major Histocompatibility Complex (MHC) Antigens
The MHC superfamily of molecules are hetero-dimeric cell surface
receptors that function to present antigen peptide fragments to T cells
responsible for cell-mediated immune responses. MHC molecules can be
subdivided into two groups on the basis of their structure and function:
Class I molecules present intracellular antigen peptide fragments (~10
amino acids) on the surface of the host cells to cytotoxic T cells; Class II
molecules present exogenously derived antigenic peptides (~15 amino
acids) to helper T cells.
MHC molecules comprise two chains. In Class I the alpha chain is
composed of three extracellular domains: a transmembrane region and a
a?
cytoplasmic tail. The beta chain (beta-2-microglobulin) is composed of a
single extracellular domain. In Class II, both the alpha and the beta chains
are composed of two extracellular domains, a transmembrane region and a
cytoplasmictail. It is known that the Ig constant chain domainsanda single
extracellular domain in each type of MHC chains are related. These
homologous domains are approximately one hundred aminoacids long and
include a conserved intradomain disulfide bond. Members of the
immunoglobulin superfamily are found in hundreds ofproteins of different
functions. The existences of such regions of structural homology predict an
identification system of adequately high sensitivity to distinguish these
similar proteins. Antibodies are unlikely to provide sufficient
discrimination. Such a system requires the precision of a molecular
biological hybridization technique.
2.13.1: Gene: HLA-A (Class I)
The HLA-A gene, also known as HLA-A.1 or HLA-J maps on chromosome
6, at 6p21.3. It encodes protein products that localize in membrane and are
involved in immune response. Its sequence produces, by alternative
splicing, 34 different transcripts altogether encoding 34 different protein
isoforms. There are 10 probable alternative promoters and 7 non
overlapping alternative last exons. The transcripts appear to differ by
truncation of the N-terminus, truncation of the C-terminus, presence or
absence of 37 cassette exons or commonexonswith different boundaries.
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HLA-A belongs to the MHC Class I heavy chain paralogues. This class I
molecule is a heterodimer consisting of a heavy chain and a light chain
(beta-2 microglobulin). The heavy chain is anchored in the membrane.
Class I molecules play a central role in the immune system by presenting
peptides derived from the endoplasmic reticulum lumen. They are expressed
in nearly all cells. The heavy chain is approximately 45 kDa andits gene
contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3
encode the alpha-1 and alpha-2 domains, which both bind the peptide, exon
4 encodes the alpha3 domain, exon 5 encodes the transmembrane region,
and exons 6 and 7 encodethe cytoplasmic tail. Polymorphisms within exon
2 and exon 3 are responsible for the peptide binding specificity of each class
I molecule.
2.14: Gene: B2M,protein beta-2 microglobulin
This gene B2M,also known as RNF36 or Trif, maps on chromosome 15, at
15q21-q22.2. The gene is expressed at very high level in a wide range of
epithelial and reticuloendothelial cells. The sequence produces, by
alternative splicing, 40 different transcripts altogether encoding 35 different
protein isoforms, all of which are involved in the presentation of
endogenous antigen. There are 7 probable alternative promoters and 5 non
overlapping alternative last exons. The transcripts appear to differ by
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truncation of the N-terminus, truncation of the C-terminus, presence or
absence of 22 cassette exons or common exons with different boundaries.
The MHCplaysa vital role in the interaction between a numberofcells
including those of the immune system. Reduction of Class I antigens has
been reported in a number of tumours. In bladder cancer, this reduction is
’'’. These antigens are the main target forassociated with poor surviva
natural killer cells (NK) which destroy cells displaying foreign genetic
material after cell interactions such as those infected by viruses or which
have undergone malignanttransformation. In situations where expression of
MHCClass II molecules become down-regulated, or “masked” bysialic
acid, affected cells appear to remain immunologically undetected and
therefore not susceptible to immuneattack. Such situations are common to
all malignancies”'®.
2.15: Gene: HLA-A (Class I)
Gene HLA-DOB.2.2, also known as HLA-DRB3, HLA-DR3B, HLA-
DOB.2, HLA-DRB2 or TAP2.2, maps on chromosome 6, at 6p21.3. It
encodes an HLA DR-beta-I precursor. The products have Class If MHC
antigen activity and are involved in immune response and localize in
membrane.
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HLA-DRB3belongs to the HLA Class II beta chain paralogues. This Class
II molecule is a heterodimerconsisting of an alpha (DRA) and a beta (DRB)
chain, both anchored in the membrane.It plays a central role in the immune
system by presenting peptides derived from extracellular proteins. Class II
molecules are expressed in antigen presenting cells. The beta chain is
approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes
the leader peptide, exons 2 and 3 encode the two extracellular domains,
exon 4 encodes the transmembrane domain and exon 5 encodes the
cytoplasmic tail. Within the DR molecule the beta chain contain all of the
polymorphismsdefining the peptide binding specificities.
2.16 Conclusions
In urinary bladder epithelium, both papillary and flat neoplastic lesions
contain twocell populations, one superficial and the otherinvasive, the
latter portending an aggressive phenotype with poor prognosis.It is likely
that these different cell subsets could (and should) be differentiated by gene
expression and gene mutation analysis. This is the subject of greatest
diagnostic and prognostic dilemmaandalso the area in which bladder
cancer mayproveto be a paradigm for manyother epithelial neoplasms,
henceyielding insights into general mechanismsof cancer progression that
currently eludes study of more complex glandular malignancies.
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Presently, immunohistochemical reagents (antibodies, lectins etc.) are
widely used in analysing malignancies.In this laboratory, staining of
bladder tumour samplesis routinely performed using a panel of monoclonal
antibodies, including those to the protein products of many of the genes
discussed in this chapter. There are numerous examples,particularly in the
bladder, of the adjunctive value (both clinical and pathological) of knowing
detailed phenotypic features of each individual malignancy. These markers
are not only valuable in discriminating normal from reactive and neoplastic,
but also in identifying tumoursthat will progress rapidly from thosethat are
relatively quiescent. For example, a high level of the proliferation marker
Ki-67 is seen in metastasising cells, as is the over-expression of Her 2/neu.
Decreased levels of pRb indicate that a mutation has occurred andthat their
tumoursupressor gene hasbeeninactivated. The reverse is seen in p53 since
increased levels indicate the mutated form becauseit is more stable than the
wild type, resists degradation and accumulatesin the nucleus. Loss of
expression of CD44, and decreased levels of Class I HLA antigens, are both
expected in samples where bladdercanceris present.
Knowledge of gene-structure, particularly from the Human Genome
Database, has revolutionized our understanding of genetic factors in many
neoplasmsincluding bladder tumours. This knowledgehasparticularly
emphasizedthe limitations of all antibodies employed to phenotype solid
tumours andthe necessity to transfer to molecular biologically-based
analytical systemsas quickly as possible. First, immunohistochemical
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systemsare labour-intensive and cannot be readily automated. They
generate data which are derived from different parts of a tumour and hence
are not exactly identical. Second, the antibodies currently employed are
frequently poorly-defined with respect to their precise epitopes. Such lack of
precision is no longeracceptable.It is important to understand the biological
function(s) of the individually spliced domains of manyofthe proteins
involved in the different stages of neoplasia, invasion and metastasis. Third,
to continue to employ current immunohistochemical techniques, splice
variants that differ between different tumours as well as between a tumour
and its normal tissue counterpart require, for their detection, a separate
antibody for eachdistinct spliced variant peptide sequence. Generation of
antibodies with necessary levels of specification and sensitivity represent an
enormoustask and may even be biologically impossible. However,it is the
expression and assembly of each spectrum of splice variants that determines
the individuality of each tumour.
Finally, during the evolution and progression of an individual cancer,
involved genesare frequently both heterogeneousandin flux with respect to
their expression. Many genes contain numerous sequencesthat are not only
differentially-spliced but may be underthe control of different promoters at
different times. Someregionsare replicated in many different proteins.
Meaningful analysis of such complexity requires the use of techniques
significantly different from those currently employed. Those novel
techniques will not only provide the necessary specificity to distinguish
neoplastic from normal, hencerefining the pathological diagnosis but will
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also providethe basis for biologically-appropriate therapeutic modulation of
bladder cancers - and thereafter of other tissue malignancies.
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Chapter3:
Patients and
Methodology
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Transitional cell carcinomas are grouped according to morphological
criteria into flat and papillary types. Throughout the Western world, the
cause oftherelentless rise in transitional cell carcinoma is unknown-
particularly since the carcinogenic properties of aniline-based chemicals
have been recognized and the substanceslargely eliminated from industrial
and domestic use. A variety of different factors including cigarette smoking
have been suggested,as etiological agents, with little robust confirmation. In
Liverpool/Merseyside the incidence of bladder canceris above the national
average””. The reasons are unknown. However, the high concentration of
industries manufacturing and using carcinogenic agents in this geographic
region, together with the generally high level of cigarette smoking
throughout the UK population,are likely important contributors to the
observed pattern of urothelial transitional cell cancers.
For manyyears, the diagnosis and monitoring of urothelial cell bladder
cancer has been made by morphological evaluation; principally the
assessment of growth patterns of individual neoplasmsaccording to
generally-agreed criteria. However, a majordifficulty frustrating subsequent
effective clinical managementof urothelial cancersis the inability of
unassisted morphologyto distinguish early lesions that progress rapidly, and
hence should receive aggressive systemic or radical local treatment, from
those that develop in an indolent mannerand can be safely managed more
circumspectly. Despite continuous monitoring, transformation of formerly
indolent cancers to ones that become invasive cannotbe predicted by
growth pattern and are only recognised after local or distant dissemination
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has occurred. Furthermore, morphological examination cannotdistinguish
between cancersthat will respond to intravesical cytotoxic therapy
(mitomycin-C or BCG)andthose that are, from the outset, chemotherapy-
resistant. These difficulties are compounded even further with respect to the
“flat” lesions — either those diagnosedforthe first time (and may include
non-neoplastic reactive, regenerative or dysplastic lesions) or those that are
neoplastic and present following treatment of a previouspapillary lesion.
Morphologically, these lesions may appearindistinguishable from “normal”
bladder mucosa, and yet are known from flow- and image-cytometric
studies’”? to contain severe chromosomal and DNA abnormalities with the
consequencethat neoplasia and invasive malignancy invariably develops in
those areas. Even after local or systemic treatment, there are no
characteristic morphological features by whichthe efficacy of a particular
treatment might be assessed.
Hence,there is an urgent clinical and pathological needto refine the
diagnosisandclassification of human bladdercancer in order to provide
informationthat is biologically and clinically relevant to each individual
patient and to each cancerthanis currently available. Genetic abnormalities
are knownto correlate with specific forms of bladder cancer. The
investigations into molecular biology of bladder cancer will aim to provide
an enhanced understanding of the pathogenesis andcreate an efficient
profiling system capable ofdistinguishing low- and high-risk malignancies
within each stage. This attemptto classify patients into increasingly well-
defined groups based on characterisation of genetic abnormalities and
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anticipated natural history should help individualise treatment strategy with
therapy becoming moreeffective and potentially less toxic.
This approach requires a detailed “phenotypic analysis” in order to identify
the particular pathway of carcinogenesis being followed by each cancer and
the particular phenotypic stage reached by each cancerat any defined point
in time. Therefore, with the objective of breaking this deadlock, a
multiparametric phenotypic analysis has been performed using antibodiesto
a series of markerproteins that are recognized to define aspects of the
biological properties of human bladder cancers.
In the United Kingdom,routine use of modern tissue-based techniquesto
provide a phenotypic profile of individual bladder cancers lags behind the
standard practice now followed in more advanced countries such as the
USA,The Netherlands, Belgium and some other European countries.
Phenotypic profiling by means of immunohistochemistry (IHC), an
antibody-based protein expression assay represents the most important and
commonly used ‘molecular’ technique in diagnostic histopathology” and is
a powerful approachthat provides valuable information onthe biological
status of individual bladder cancers. IHCis an analytical process relying
uponthe specificity of an antibody (mono- or polyclonal) directed towards
specific antigens present within a given tissue. This process involves
incubation of tissue sections with an appropriately diluted primary antibody
followed by detection by meansofa suitable detection system. Antibody
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presence andlocalisation on the tissue section’can then be characterised
both for the relative amount anddistribution of specific proteins in a
particular tissue.
However, IHC remained quiescent asit required fresh or frozen material,
until Masonetal.””° reported the ability to detect antigens in formalin fixed
paraffin embeddedtissues. The widespread diagnostic applicability of IHC
waswith the discovery of antigen retrieval methods. This process involved
proteolytic digestion of tissue sections, followed by microwaving or
pressure cookingoftissue sections in a variety of different buffers’. IHC is
now a powerful investigative tool supplementary to H&E tissue morphology
and generates diagnostic accuracy, prognosis and therapeutic information in
io ‘ ; 9)specific areas where morphology alone remains inadequate saad
eal
This study examined a panel of potential biomarkers previously reported to
provide adjunctive information in several different malignancies which are
discussed below:
Ki-67 protein has been demonstrated to be a good indicatorof proliferation
in a variety of tumours; expressedin all cells in G1, S and G2M phases but
not in cells in GO phase, allowing assessmentofthe entire proliferating cell
pool. Expression of Ki-67, a marker of proliferation, accurately
demonstrates the rate of cell proliferation in a lesion. High rates of
proliferation are recognized to increase the risk of malignant transformation
and progression in a variety of neoplasms and hence regarded as a predictor
»» 225 226 Normal bladder epithelium has a lowof tumour “aggressiveness
proliferation rate, as defined by Ki-67 expression. Thus, Ki-67 assessment
provides a numerical value for cell proliferation that is a quantitative index
of progression “risk” for each lesion. The CDKN2agene(p16) is a critical
inhibitor of cyclin CDK complex, andits inactivation is thought to permit
progression through G1/S cell-cycle checkpoints””” 28 This loss of p16
function leads to the loss of Rb tumour suppressor function and,
consequently up-regulation of cell cycling’ 29 It is also at the G,/S
restriction point that wild-type p53 (in response to cell damage) induces
waflWAFI genetranscription with the resulting p21 protein binding and
inactivating the cyclin/cdk complexes. The consequent accumulation of
hypophosphorylated pRb blocks E2F-dependanttranscription leading to cell
230cycle arrest™ . Use of immunohistochemical markers to tumour suppressor
genes p53, Rb and PTEN allows accurate identification of genotypically
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abnormal lesions- and hence of differentiating between reactive and
potentially neoplastic epithelium. Expression of p53 is a particularly
powerful discriminator in early lesions, being absent in reactive epithelium
and positive in approximately 80% of neoplasms, which cannot otherwise
be segregated according to unassisted morphologicalcriteria 231232PTENis
a tumour suppressor gene mapped to chromosome 10g. Studies for loss of
heterozygosity or allelic imbalance have showndeletions in 4 of muscle
; . ; 33 23invasive tumoursbut only in <7% ofsuperficial tumours”? ***,
2” appear to exhibit a reciprocalBcl-2”° andcell-surface receptor c-erb-B
relationship in neoplastic urothelial lesions. Loss of normal expression of
bel-2 by urothelial basal epithelial cells and de-novo expression of c-erb-B2
are early cellular changes that accurately define the neoplastic phenotype
and hence predict development of bladder cancer-of either flat or papillary
types. The apoptotic modulator Bcl-2 proto-oncogene appears to increase
cell longevity by regulating a downstream eventleading to the induction of
apoptosis, thereby allowing cells to escape apoptosis”. The bcl-X geneis a
homologue of the bcl-2 gene which has demonstrated different patterns of
expression and thus suggested to regulate different stages in the execution-
phase of cellular death'”’. Bcl-X, is the longer alternative protein transcript
encoded by bcl-X and suppresses cell death with the shorter bcl-Xs which
promotesapoptosis”.
2367Expression of homeostatic regulator protein hsp-2 is an accurate and
powerful markerof bladderurothelial cells, as well as being intimately
93
involved in modulating the responseofcells, of both normal and neoplastic
types, to expression and activation of oestrogen receptor proteins.
Potentially, it is an extremely valuable reagent with whichto identify single-
cell invasion across the basement membraneandinto the sub-epithelial
stroma; thus changing the pathological grade of an early cancer from that of
pTa (in-situ cancer) to pT1 (microscopically superficially-invasive). These
are notoriously difficult lesions to diagnose accurately such that use of an
independentand objective markerofepithelial cell invasion is highly
desirable and would be extremely valuable.
Finally, the role of oestrogen receptor expression in urothelial carcinoma
has not been extensively analyzed. Oestrogen function is mediated through
two specific intracellular receptors ER- a and ER- B which play important
roles in mediating nongenotropic oestrogenic effects”*”. Studies”*** have
shownhigherlevels of ER expression in humanurothelial carcinoma
suggesting that oestrogen receptors may play a more importantrole in the
biology of human bladder cancer.
Therefore, the objective of this part of the overall study was totest the
hypothesis that objective phenotypic analysis of urothelial lesions with
selected markerproteins, using commercially-available antibodies,
identifies some of the important proteins responsible for promoting and
determining the stage of individual human bladdercancers. It was
anticipated that the data from the selected panel of antibodies would provide
novel reliable information, not otherwise available, to accurately predict the
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pathological and clinical behaviorof particular urothelial neoplasms and
hence improve the managementstrategies of individual patients with
bladder cancer.
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3.2: Patients
3.2.1: Cases Studied
A cohort of 138 patients referred for managementof urothelial neoplasia to
the Multidisciplinary Team Meeting (MDT)for Urological Malignanciesat
the Royal Liverpool and Broadgreen University Hospitals (NHS) Trust,
Liverpool, UK, were recruited sequentially and unselected to this study.
These were patients who had had bladder tumour diagnosed following
investigations for visible or non-visible haematuria, other lowerurinary tract
symptomssuchas urinary frequencyor recurrenturinarytract infections.
All patients had an initial cystoscopy evaluation of the bladder under
general anesthesia with resection of bladder tumour for conventional
histological reporting. These patients were reviewed longitudinally over
time with respectto their clinical and pathological status at each
presentation to the MDTfollowing the initial histopathological diagnosis of
urothelial carcinoma. All original H&E stained tissue sections, and their
accompanying paraffin wax tissue blocks, were retrieved from the archives
of the Department of Pathology at the Royal Liverpool and Broadgreen
University Hospitals (NHS) Trust. The morphological appearances of each
biopsy specimen were reviewed to confirm the diagnosis and to ensure
consistency of the reported pathological grade and stage. These tissue
blocks were held within the Pathology archive in the Department of
Pathology, University of Liverpool. Histological sections were cut at 4 um
thickness from formalin-fixed and paraffin wax-embeddedtissues and
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processed as described previously~”. Additional sections were then cut from
the paraffin wax-embeddedtissue blocks and stained using the panel of
selected antibodies.
All 368 tissue sections were examined independently by urological
pathologists for histological staging using the H&E stained specimen. The
biomarker grading was undertaken independently with positive staining
scored from 1-3 (0 being negative) with three being strongly positive.
 
 
 
 
 
Diagnosis Numberofpatients
Normal (Control) 17
No abnormality 11
Chronic inflammation 5 (1)*
Non-muscle Dysplasia 4
Invasive CIS 9 (1)*
Carcinoma pla 38 (1)*
pTl 27 (4)*
Muscle invasive pI2 16
Carcinoma >pT3 4
TOTAL 131     (n)*- non-muscle invasive carcinomato invasive disease;
Table 3.1: Patient Demographics- FINAL COHORT
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3.2.2: Controls
Control bladder tissue specimen were selected randomly but over the same
period of time as the cases studied, from patients biopsied for histologically-
confirmed non-neoplastic conditions of the urinary bladder. These
specimens were assessed morphologically and byclinical follow-up to be
free from neoplastic disease, particularly of the urinary bladder. Sinceall
those patients presented for investigation of probable underlying
inflammatory disease, but not neoplasia, they were typically both female
and also youngerthan the cases studied.
Forthis analysis, it was irrelevant that these control cases are not age- and
gender- matched tothe cases studied, since no therapeutic outcome was
being assessed. Therefore, these controls were appropriate to exclude any
effects of neoplastic disease. The purposeofthis study wasto identify
phenotypic changesthat could be attributed to neoplastic disease of the
urinary bladderirrespective of age, gender or the presence of inflammation.
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3.3: Ethical Approval
This study was approved by the Liverpool (Adult) local Research Ethics
Committee (LREC) in their advisory capacity to the Cheshire & Merseyside
Authority (03/04/016/A)
3.4: ImmunohistochemicalStaining
Sections of each specimen were cut at 44m from formalin-fixed, paraffin-
embeddedtissue blocks onto APES (amino-propy]tri-ethoxysilane) —coated
glass slides and dried overnight in an ovenat 56°C. Thefixation and
processing of tissues can have a ‘masking’ effect upon someofthe antigens
within them. Various pre-treatments have been devised which may be
applied to tissue sections to reverse this masking effect, and allow primary
antibodies to recognize and bindto their target antigens.
3.4.1: Pre-treatment:
Sections were treated with methanol/H2O>for 12 minutes to remove the
paraffin wax followed by rehydration through graded ethanols. Endogenous
peroxidase activity was blocked by immersion in a 3% (w/v)solution of
H,0> in methanol for 12 minutes. Sections were then rinsed in tap water
followed by deionised water.
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Pre-treatment with trypsin and calcium chloride (Becton-Dickinson, Difco
0152-13), pepsin (Sigma P-7000) and protease XXIV (Sigma P-8038) was
undertaken for 15-30 minutesat 37°C.
3.4.2: High Temperature Antigen Retrieval
High temperature antigen retrieval was performed using a domestic
stainless-steel pressure cookerat full-pressure for 3 minutes in 10 mM
EDTA(Ethylenediaminetetraacetic acid) solution (pH 7.0) and immediately
cooled by running the pressure cookerinto a sink of cold running tap water.
High Temperature Antigen Retrieval (HTAR) combined with Trypsin
Digestion:
Sections become extremely sensitive to the effects of proteolytic digestion
after they have been subjected to HTAR.This is especially true of sections
subjected to HTARusing the pressure-cooker in which digestion time must
be controlled very precisely.It is preferable to use the microwave method
when HTARis to be combinedwith digestion”.
HTARwasperformedas described above. The sections were then washed
in tap water and rinsed in deionised water. Sections were then placed in
trypsin solution at 37°C for an exactly timed 20 minutes and then washed
well in running tap water.
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3.4.3: Immunohistochemistry
The technique used in our laboratory was the commercially available
DAKOEnVision™+ System, Peroxidase (DAKO EnVision™+ System,
HRP)for the qualitative identification of antigens by light microscopy in
normal and pathological paraffin-embeddedtissue preparations.
The DAKO EnVision™+ System, HRP is a two-step immunohistochemical
staining technique (Figure 3.1).
A tissue antigen OQ peroxidase enzyme
molecule
Xd primary antibody
‘dextran backbone
goat anti-mouse or
anti-rabbit antibody
Figure 3.1: DakEnVision™ + System, HRP two-step immunocytochemical
staining technique
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This system is based on a horse-radish peroxidase-labelled polymerthat is
conjugated to secondary antibodies. The labelled polymer does not contain
avidin or biotin. Consequently, nonspecific staining resulting from
endogenousavidin-biotin activity is eliminated or significantly reduced. The
kits were species specific; EnVision (mouse) used with mouse monoclonal
antibodies and EnVision (rabbit) with rabbit polyclonal primary antibodies.
After appropriate pre-treatment and HTARasdescribed above, the slides
were transferred to an automatic immunostainer (Sequenza®). After
equilibration in fresh Tris Buffered Saline comprising 0.05M Tris (pH 7.6)
containing 0.12M NaCl and 0.05% Tween-20 (TBS-T), sections were
incubated with primary mouseor rabbit antibody or negative control reagent
(100uL of 5% bovine serum albumenwasapplied), followed by incubation
with 100uL of the labelled polymer, using two sequential 30-minute
incubations. Staining was completed by a 10 minute incubation with 100uL
of 3,3’-diaminobenzidine + substrate-chromogen and washedin deionised
water and running tap water. Finally, the sections were counter stained with
haematoxylin solution. The end results were a brown-colouredprecipitateat
the sites of antigen-antibody binding andthe nucleistaining blue.
3.4.4: Primary Antibodies
These were selected based on the current evidence in literature and
commercial availability. Staining protocol for the cell-cycle regulatory
proteins were all monoclonal mouseanti-humanantibodies. Table 3.2 lists
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the primary antibodies used for staining the various proteins. Samples with
knownpositive reactivity for each monoclonal antibody were used as
positive controls. As a negative control, a section was processed in which
the primary antibody was changed by PBS.
 
 
   
Protein Primary Antibody
Ki-67 MIB-1; 1:200, DAKO,Carpinteria, CA~”
ER- a Mouse monoclonal 1:200, Bio- Genex, San Ramon, cA
ER- 8 monoclonal antibody ER(Dako, K1900)°"°
Hsp-27 Mouse monoclonal p27kip! (Dako, Glostrup, Denmark)”
p53 Mouse monoclonal PAb 1801, 1:50 (Dianova, Hamburg,
Germany)"8
pRb RBI, Dako, 1:75*”
p21 Ab1, Oncogene Science, Cambridge, MA, 1:20°°
pl6 Mouse monoclonal, NeoMarkers, 1:50°”
PTEN Polyclonal anti-PTEN, 1:100 (Upstate Technologies)”
c-erb-B2 Polyclonal, 1:200 (Dako Corp., Carpinteria, CA)”
Bcl-2 Mouse monoclonal, 1:40, Dako Laboratories, Carpentaria, CA’
Bcl-x, Polyclonal, 1:150, Zymed Laboratories, San Francisco, CA*®
Table 3.2: Panel of Biomarkers
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3.5: Qualitative Scoring of Markers
The biomarkers were independently assessed for each tissue section as
either negative, weakly positive or only focally positive (low-level
expression), or strongly positive (high-level expression) and scored as0, 1,
2 or 3, respectively with 1- being mildly positive and 3- being strongly
positive. Specimens were considered positive only whenat least 5%-10% of
the contained urothelial cells (either normal or malignant) unequivocally
expressed the biomarker.
3.6: DATA ANALYSIS
Individual cancer diagnosis and biomarker expression were used in the
statistical analysis of the collated data.
The cancer patients were categorised into 5 distinct groups based on the
grade of malignant transformation and stage of tumour invasion. Patients
who were known to have a history of malignancy and a negative index
biopsy which had been undertaken for suspected recurrent malignancy (no
abnormality detected) or histological evidence suggestive of varying degree
of chronic inflammation were grouped together. Dysplasia, carcinoma-in-
situ and pTa bladder tumours were categorised together, pT! bladder
tumours considered a separate entity; and muscle invasive tumours, a fifth
group.
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This grouping of the patients was aimed at enhancing the relationship
between the stage of the disease (1 representing the normal controls, 2 being
the group with no detected abnormality or chronic inflammation through to
5 representing muscle invasive disease) and the biomarkers with an
emphasis on the non-muscle invasive urothelial cancer (pTa/ pT1 tumour).
The biomarker scoring system was dichotomised with zero and one classed
as negative and twoandthree consideredpositive.
Calculations were performed using the Statistical Package for the Social
Science Version 17.0 (SPSS Inc., Chicago, IL, USA). Non-parametric test
statistics were used to identify the significant association between the
urothelial carcinomastages and the corresponding biomarkers. The resulting
stage groups were used as dependentvariables in the binary calculations and
the calculations were repeated for different methods to ensure numerical
accuracy andreliability.
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Chapter4:
Results
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This study cohort comprised of 368 index bladder specimens from 138
patients assessed pathologically for urothelial carcinoma. However, the
tissue blocks from six patients contained too little material and hence were
inadequate for immunohistochemical staining and analysis. These were
therefore excluded from the final analyses. One patient diagnosed to have
squamouscell carcinoma wasalso excluded from the study.
The final cohort comprised 131 patients with adequate biopsy tissue for the
complete analysis with the panel of 12 biomarkers. 114 patients had
diagnosed urothelial carcinoma and 17 patients who were considered as
controls. These latter were patients with benign disease who had been
investigated for inflammatory/infective disorders.
The control group comprised 19 index bladder biopsies from 17 patients.
The mean age of this group was 50 years (range 21-86 years; SD 20). 12
were female with only 5 being male. In the cancer group, were 312 index
biopsies/resections deemedsuitable for analysis. The mean age of the cancer
group was 68 years (range 30-9lyears; SD 13). 82 of these patients were
male and 32 were female.
Within this group, 79 patients were diagnosed pathologically to have non-
muscle invasive urothelial carcinoma. Of these, seven developed invasive
disease. On primary bladder tumourresection, 20 patients were diagnosed to
have muscle invasive disease and later underwent radical treatment. A
further two patients were treated conservatively with static disease.
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In the non-muscle invasive disease group over 13 years, there was an
increase in stage (e.g: pTa-pT)) in seven patients. No change in the stage
was recorded in eight patients and a decrease occurred in stage in six. 15
patients had either a benign or inflammatory histology when urinary bladder
lesions were biopsied/resected as part of their urinary bladder follow-up.
The immunohistochemical staining characteristics are contained in Table
4.1. The test data (Kruskal-Wallis Test) comparing the individual
biomarkers and the stages are contained in Table 4.2. Of the total panel of
biomarkers, the indices Ki-67, p53, bcl-2, Bcl-X_, ER-B and c-erb-B2
indices revealed significance (p < 0.05) with respect to prognosis suggesting
that these biomarkers may have independentassociation with tumourstage.
On decreasing the p-value to p < 0.001, only Ki-67, p53, bel-2 and c-erb-B2
were identified to have a distinct ordinal relationship between the marker
values and the tumourstage.
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Ki- Bel- Bel- PTE © Hsp67 P 53 Rb 2 p21 pl6 X, N Era ErB ~ 27
O ss 44 29 179 105 37 104 96 128} 161 23 8
1 91 716 60 710 60 19 10 63 2 66 44 19
2 80 86 14 28 37 9 5 54 0 37 82 51
3 31 95 197 24 18 10 2 67 0 25 135 179
Total 290 301 300 301 220 75 121 280 130 289 284 257
Table 4.1: Expression of Individual Biomakers in the Study Cohort
c-Ki- Bcl- Bel- PT Er Er Hsp67 P 53 Rb p21 pl6 X, EN B erb 27
-B2
Chi. 64.9 16.35 5.45 53.8 2.7 7.03 10.8} 7.0 0.0 10.6 24.2] 2.5Square
Df 4 4 4 4 4 4 4 4
p value .00 .00 24 00 .62 03 13 1.0 .03 .0O0 .65            
Table 4.2: Individual Biomarkers and Analysis with Stage Group
(Kruskal-Wallis Test)
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4.2: Control group
The control group consisted of 17 patients who had hada total of 19 bladder
biopsies. The biomarkerstaining characteristics of this group of patients are
in Table 4.3. 15 patients had only one bladder biopsy with no secondary or
follow-up procedure performed due to the benign histology. Two patients
had two biopsies which were taken during the same procedure.
To identify their significance, all immunohistochemical staining was
dichotomised as negative (scores of zero and one) and positive (two and
three) and subsequentanalysis performed. Descriptive statistics suggest that
the biomarker expression for true normal would describe the following
pattern:
POSITIVE-- Rb, erb-B2, Hsp-27
NEGATIVE—Ki-67, p16, Bcl-X,_, ER-a
 
Ki- p Bel- Bel- PTE Er Er - Hsp-67 53 RD 2 pal ple _ 27
Neg(0,1) 19 11 3 6 16 14 2 14 2 11 2 1
Pos (2, 3) 0 7 164 11 3 1 0 4 0 8 17 18
%post O 39] 84} 65 16] 7 O 22 0 42} 90 95              
Table 4.3: Expression of Indivudal Biomarkers in normal (Control) patients
(17 patients, 19 biopsies)
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4.3: Non-Muscle invasive urothelial carcinoma group
This group includes the morphological system of neoplasia and involving at
most the lamina propria. The analysis was performed only after combining
various stages into groups. Thus dysplasia, carcinoma in-situ and pTa
disease were classified into one group. pT, disease was considered as a
separate group.
Four patients diagnosed with dysplasia, one of who later developed pT
disease seven monthslater. Nine had carcinoma-in-situ (CIS) disease with
all but one having static disease. One patient with CIS developed muscle
invasive disease at four years from initial diagnosis. The majority of patients
with superficial disease had pTa disease (38 patients). Four of these patients
developed pT, disease (mean 6.Syears, range: 2-1lyears) and one patient
developing pT>2 disease (after 13 years).
27 patients were diagnosed to have pT; disease. Four of these patients
developed muscle invasive (pT2) disease. Three were upstaged on the
immediate re-resection (<6 months-<lyear) and the fourth patient was
upstaged within three years. In this sub-group the confounding factoris that
these patients could have been under-staged withtheinitial resection biopsy
as the interval between the initial biopsy and the second/further biopsies
resulting in the upstaging was a short duration. pT; disease was down-
graded in three patients to chronic inflammation, dysplasia and pTadisease.
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Descriptive statistics suggest that the biomarker expression for the non-
muscle invasive urothelial carcinoma (Dysplasia, CIS and pTa disease)
would describe the following pattern (Table 4.4):
POSITIVE—53, Rb, c-erb-B2 and hsp-27.
NEGATIVE—Bcl-2 and Bcl-X_.
In the pT, disease subset, changes in the biomarker expression pattern were
more pronounced (Table 4.4):
POSITIVE—}5S3, Rb,c-erb-B2 and hsp-27.
NEGATIVE—Bcl-2 and Bcl-X_.
There were more positive cases of Ki-67, p53 and Rb in comparison to the
dysplasia, CIS and pTadisease group.
Statistical analysis of the biomarker expression overthree stages (Table 4.5)
using a 2-tailed Mann-Whitney U test model compared normal group
(control) histology versus group 3 (dysplasia, CIS & pTa) and then versus
pT,disease. Initial comparison ofthe normal (control) group versus group 3
(dysplasia, CIS and pTa disease) showed that of the total panel of
biomarkers in early non-muscle invasive disease; Ki-67, Bcl-2, p16, PTEN
and ER-B revealed significance (p<0.05) with respect to prognosis
suggesting that these biomarkers may have significant association with
tumour stage. On decreasing the p value to < 0.001; only Ki-67 and Bcl-2
were identified to have a distinct ordinal relationship between marker values
and the tumour stage. In comparing the controls versus pT; disease; Ki-67,
p53, Bcl-2 and p16 were significantly (p<0.05) correlated. However, only
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Ki-67 and Bcl-2 maintained this association when the p-value was
decreased to p<0.001.
The analysis also revealed a significant association with Ki-67 and p53
when comparing dysplasia, CIS and pT; disease with pT) urothelial
carcinoma.
A significant increase was identified in Ki-67 expression from non-
neoplastic tissue through early non-muscle invasive carcinoma to pT)
disease. Up-regulation of p53 and p16 wasalso seen. There waslossof bcl-
2 expression and ER-B down-regulation. ER-a expression was negative
acrossall stages.
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Figure 4.1: Ki-67 expression pattern by stage
(NMI- Non-muscle invasive; MI-muscle invasive disease)
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Figure 4.2: Bcl-2 expression pattern by stage
(NMI- Non-muscle invasive; MI-muscle invasive disease)
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Ki- Bel- Bel- PTE Er © Hsp67 P 53 Rb 2 p21 pl6 X, N ‘i Er B oe 27
te so 80 s4 11 23 10 (| 56 o 26 102 94or 39) (62) 64) (8) 726) B7 (46) ©| (21) (84) (0)
t 34} 40 39 yf | 5 2 17 0] 10 44 apT) 71) 78) 07) (31) (39) ao) G6) © (20) 6) (87)
number(%)
Table 4.4: Positive expression of Individual Biomarkers in non-muscle
invasive urothelial carcinoma (79 patients, 185 biopsies)
 
             
c-p Ki- Bel- Bel- PTE Hsp
values 67 pss) Bb 2 pat pis XL N mat ey -27
NO vsGp 3* 0.00 0.07 0.08 0.00 0.33 0.03 0.87 0.06 0.05 0.51 0.49
N vspT 0.00 0.00 0.49 0.00 0.24 0.05 0.66 0.29 0.06 0.72 0.371
Gp 3*
vs 0.00 0.03 0.11 0.60 0.64 0.93 0.10 0.27 0.87 0.66 0.68
pT)
*Group 3-(Dysplasia, CIS, pTa). N-normal
Table 4.5: Comparison between Non-Muscle Invasive Urothelial Carcinoma
Groups and Normal Bladderbiopsies
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4.4: Muscle invasive urothelial carcinoma group
This group comprised of patients diagnosed to have pT2, pT3 and pT,
urothelial carcinomaat initial diagnosis. Within this group, 20 patients were
diagnosed with muscle invasive disease. 16 had pT disease with three
having pT3 and one with pT, urothelial carcinoma. Almostall these patients
were then treated radically with either cystectomy or radiotherapy. Two
with pT. disease were treated conservatively and remained with stable
disease at ive and eight years follow-up. Seven patients initially diagnosed
with non-muscle invasive bladder carcinoma and then developed muscle
invasive disease were included in this group for analysis.
In these patients with aggressive muscle-invasive urothelial carcinoma; the
biomarkerprofiling pattern was as below (Table 4.6):
POSITIVE— Rb,Bcl-2 and hsp-27.
NEGATIVE— ERB.
 
Ki- p Bcl- Bcl- Er Er c-erb- Hsp-67 53 RP] 2 P2t| ple} x PTEN| | 5 B2 27
“a 7/9 174] 2 |13) 4 4]9 17 12} 27 10 -
Positive(2, 3) 18 19 21 25 6 1 3 10 0 1 16 19
%
positive 72 70 75 93 32 20 25 37 0 4 62 83
biopsies               
Table 4.6: Expression ofIndividual Biomarkers in Muscle Invasive
Urothelial Carcinoma
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Mann-Whitney U test analysis (Table 4.7) suggests a significant up-
regulation of Ki-67 and Bcl-2 with marked loss of ER-B and c-erb-B2 in
muscle invasive urothelial carcinoma in comparison with non-neoplastic
bladder biopsies. This strong association persisted even with p< 0.001
except for c-erb-B2 (p<0.05). In comparison with non-muscle invasive
(dysplasia to pT; disease) urothelial carcinoma, the urothelium significantly
gained Ki-67 and Bcl--X, with down regulation of ER-B and c-erb-B2 with
the urothelial carcinoma becoming muscle invasive.
Seven patients with non-muscle invasive carcinoma developed muscle
invasive disease. Sub-group analysis revealed a significant association with
prognosis with the informative biomarkers being Rb, p21, PTEN and hsp-
27. Increased expression of Rb, p21 and PTEN with downregulation of hsp-
27 suggests an increasedlikelihood of developing muscle invasive disease.
 
valiies ee p53| Rb
|
Bek p21 pis Bek pren EF erb-B2
Hsp-
Normal| 999 |0.06 0.45 0.00 0.26 0.40 0.44 0.30. 0.00 0.04 0.23vs MI*
            a 0.00 0.53 0.27 0.87 0.65 0.47 0.00 0.42 0.03 0.01 0.35NMIO 0.03 0.87 0.432 0.96 0.72 0.45 0.01 0.57 0.03 0.01 0.40vs MI*(\non-muscle invasive carcinoma; *muscle invasive carcinoma
Table 4.7: Comparison between muscle invasive urothelial carcinoma and
non-muscle invasive disease groups and normalbladderbiopsies
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4.5: Chronic inflammation / No abnormality detected (““Normal’’)
There were 77 bladder biopsies where the histological diagnosis was
chronic inflammation or “normal”. These were diagnosedin patients with
strong suspicion of urothelial malignancyor a previoustreated urothelial
malignancy. The possibility of abnormal biomarkerprofiling in these
biopsies wherethere is a significant deficiency in routine H&E staining
failing to detect/ differentiate between chronic inflammation, dysplasia and
CIS precluded the inclusion of this category in the final analysis. Statistical
analysis did reveal that this group were a distinct entity from both the ‘true’
normalbiopsies (Bcl-2, PTEN and c-erb-B2-- p<0.05) as well as the early
(dysplasia, CIS and pTa) non-muscle invasive disease (Ki-67, p53, bcl-2
and c-erb-B2—p<0.05).
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Chapter5:
Urinary Bladder Cancer Progression
Predicted at Diagnosis by Quantitative Analysis of
Ki-67 Protein Expression
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UKrates for urinary bladder cancer havefallen since their peak in the
1990’s'°. Although the incidence of TCC remains biased towards men,the
prevalence of this disease in the U.K.has altered to a male:female gender
ratio that is presently 5:2. There is concern that altered environmental
factors promote developmentand progression of TCC through hitherto
unrecognized mechanisms,especially in women 249250Formerly regarded
as a disease of the elderly, TCC is diagnosed more frequently in younger
persons, increasing its socio-economic impact. Althoughthe five-year
survival for superficial tumors (pT,-pT 1a) is good at 80-90%,survival
declines to <50% with muscle invasion (2pT>2). For bladder-confined
tumors, treatmentis limited to intravesical BCG aa mitomycin C, a
combination of both *» or to radical cystectomy °°3 Radical radiotherapy
for pT 1-G3-NX-M0Odisease is no more effective than conventional
254conservative treatments ~”. Furthermore, current therapies are complicated
5 .255 256 and theirby severe local pain, give rise to systemic complications
long-term benefits are limited *°° Thus, there is a needto target therapies to
those patients predicted to have progressive disease. While histological
assessmentat diagnosisis helpful to clinicians,it is not a good prognostic
predictor of disease progression or outcome °°7 because morphologically
similar bladder cancers are phenotypically distinct and behave differently.
To assess tumorproliferation, immunohistochemical studies have been used
as a surrogate to predict tumor aggressiveness and prognosis of other
malignancies 258259 Th addition to bladder, 260 761 the Ki-67 protein, detected
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by monoclonal antibody MIB-1, has been demonstrated to be a good
indicator of proliferation in a variety of tumors including bladder neoplasia
262 263 Ki-67 is expressedin all cells in Gj-S and GoM phasesbutnotin cells
in Go phase, allowing assessmentofthe entire proliferating cell pool 264The
Ki-67 index(i.e. percentage of a population of cells expressing nuclear Ki-
67) has been usedin prostate cancerto evaluatelikely clinical behavior and
prognosis 258265 Tn transitional carcinoma cells, Ki-67 exhibits an inverse
relationship with expression ofcell-cycle checkpoint gene CCND1 *6! The
‘point counting’ approach commonly employedto evaluate Ki-67
expression is both time-consuming andraises the probability of sampling
error. Other indices have been employedtoassessproliferation rates, with
765-67 <9 that reproducibility has been difficult to assess.varying validity
To generate objective numerical data, we developedaninteractive
computer-based analysis technique to quantify Ki-67 expression in a
reproducible manner. Weassessed Ki-67 expressionrelative to grade and
stage and have analysed variations in quantifying Ki-67 when comparing
the detailed numerical data with semi-quantitative impressions derived
following subjective assessmentof staining. Thus, the aim of the present
study wasto test the hypothesis that, in superficial bladder cancer,
assessmentof the region of maximum cellproliferation by Ki-67 expression
in a diagnostic biopsy specimenisa reliable predictor of cancer progression
and hence could be used routinely as one of the parameters to determine
individual bladder cancer management.
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5.1: Patients and Methods
This study analysed a sub-cohort of 86 of the total 368 bladder biopsy
specimensderived from 35 of the 138 patients with long-term follow-up
received in the Department of Pathology at The Royal Liverpool University
Hospital, Liverpool, UK. These were Cases were entered into the data-set on
their first schedules appointment,either as a new referral or on routine
follow-up. For patients with the prior diagnosis of bladder cancer,details of
their previous pathological investigations were retrieved, reviewed and
entered into the database. Thus, a retrospective and prospective cohort of
patients with histologically-confirmed TCC underactive surveillance was
compiled together with a series of patients in which malignancy was
excludedhistologically. Paraffin-wax blocks of morphologically non-
neoplastic archival bladder tissues and corresponding urothelial cancers
were routinely stained with haematoxylin and eosin (H&E)to establish the
histopathological diagnosis. All cancers were classified according to the
TNMclassification *°*. Followingreferral, all patients were managedin a
consistent manner through weekly multidisciplinary team (MDT) meetings
according to conventional protocols.
5.2: Immunohistochemistry
Tissue sectionsserial to those stained with H&E and usedforinitial
: . ; . . 258 wm: ;diagnostic purposes werestained for Ki-67 expression °8. Tissue sections
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were incubated for 60 minutes at room temperature with biotinylated
monoclonal antibody MIB-1 (Dako Ltd, Denmark) diluted 1:50 in
phosphate-buffered saline (PBS) before immersionin solution of 3,3’-
diaminobenzidine tetrahydrochloride (DAB, Fluka AG, Switzerland) at 250
ug/ml in 0.04% (v/v) H2O> in methanol for 5 minutes to develop the
chromagen. Negative controls comprised sections of benign and malignant
urothelium processed identically with the exception that the MIB-1 antibody
wassubstituted with PBS.
5.3: Determination of baseline scores
Following diagnosis, all H&E-stained tissue sections were reviewed by a
senior pathologist (CSF) to confirm that adequate tumor waspresent on
each section and that the diagnosis, grade and stage were standardised and
correct. All stained tissue sections were then analysed,the slides being
assigned independentscores, the observer being blinded to the data accruing
within the programme. The baseline score wasthat subjectively assigned by
the pathologist on a scale of 1-4 with “1” being no expression and 4 being
highly proliferative. A 10% cut-off was used to distinguish cases considered
negative from those with positive scores(i.e. at least 10% of nuclei had to
stain to be awarded a score >1). Following collection, these Ki-67 scores
were compared with pathological stage and grade.
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5.4: Determination of proliferation indices
All tissue sections initially scored by myself and Professor Foster were
analysed using a Zeiss KS300 image quantification system (Carl Zeiss Ltd,
Welwyn Garden City, UK) at x40 magnification. A computer programme
developed within the Division of Pathology allowed semi-automated
assessmentofpositively stained Ki-67 nuclei. For all cases examined,the
density of nuclear staining for Ki-67 was adjusted against a standard to
ensure consistency,particularly in accepting the low cut-off intensity.
Thereafter, two new indices were developed to enable automated
characterisation ofproliferation: Ki-67 percent (Ki-67p) being the ratio of
stained to unstained nuclei in the area of a selected field. Each area was
individually defined by the investigator to include only areas of epithelium
(either benign or malignant) and to exclude all non-epithelial tissues.
Conversely, Ki-67 density (Ki-67d) was recordedas the ratio of “positive”
nuclei within the sametotal area occupied by the malignantepithelial cells.
A total of 102 tissue sections from 56 patients were scored. Five separate
areas in each tissue section containing adequate malignant or benign
urothelium were analyzed. Sectionsthat did not contain five distinctly
separate areas of urothelium for analysis were excluded from the study. As a
consequence,86 sections containing adequate urothelium for five separate
and consecutive readings and wereincluded in this study. The mean values
of the five readings were usedfor analysis.
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Conventionally, during statistical analysis, all readings (for both Ki67p and
Ki67d) were assigned to one of four groups: (0-0.01 = 1, 0.01-1 = 2, 1-2 =3
and >2 = 4) where Group | was negative and Group 4 wasstrongly positive.
These groups were given equal weighting and selected to represent the
values assigned bythe pathologist during histological assessmentof each
field. Absence of staining was not assigned the score “0”but “1” because of
the mathematical implications involved in handling the term “zero”.
5.5: Statistics
Analysis of the data on the stage and gradeat diagnosis, together with
indices and baseline scores was performed using the Statistical Package for
the Social Science Version 14.0 (SPSS Inc., Chicago, IL, USA). Correlation
studies were undertaken with Spearman’s test (r,). The Kruskal] Wallis test
wasused for group comparison. For all comparisons p < 0.05 was
consideredstatistically significant.
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5.6: Results
Tissues for analysis were available from 35 patients with urinary bladder
cancer. Ofall the tissue sections stained and examined, 86 slides were
included in the analysis, all others being excluded whereverepithelial
tissues were insufficient to fulfil the requirementof at least 5 distinct fields
for analysis. Of these, 14 sections were histologically normal, 9
inflammatory, 8 dysplastic, 39 CIS/superficial bladder cancer and 16
invasive cancers. Mean age was 76 years (range: 51-94 years). There was no
significant difference in age between patients with differing grade or stage
(p=0.34). Positive nuclear staining (Score >1) was observed in 75 of the 86
sectionsin at least one of three parameters. 11 slides gave zero readings
(Figure 5.1) in all three parameters with non-malignant disease. However,
dysplastic lesions were frequently accompaniedbya focal increase in
proliferation (Figure 5.2).
A breakdownof the major groupsis given in Table 5.1. Ki-67p (p<0.01) and
Ki-67d (p<0.01) both showeda significant correlation with tumor grade and
stage. Morphologically identical lesions, both papillary and flat exhibited a
wide rangeofproliferative activity that could not be predicted from
morphological features, whether nuclear or cytological (Figures 5.3 and
5.4). This was true also for the baseline scores (p<0.01).
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Figure 5.1: Early lesion with dysplastic morphological features but no
proliferation identified by Ki=67 nuclearstaining. (magnification x240)
 
 
Figure 5.2: Flat dysplastic lesion (pTa) with focally increased proliferation
(proliferation Group 2) (magnification x240)
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Figure 5.3: Grade II papillary lesion (pTa) with only occasional proliferating cells
(proliferation Group 1) (magnification x240)
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Figure 5.4: GradeII papillary lesion (pTa) with elevated proliferation (proliferation
Group 3) (magnification x240)
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POSITIVE POSITIVE
BASELINE KI-67 KI-67P KI-67D
SCORE INDEX
Normal 4/14 6/14 <0.01 0.22
Inflammation 7/9 8/9 0.01 0.23
Dysplasia 5/8 6/8 0.21 0.79
CIS/Superficial Cancer 35/37* 39/39 0.37 2.41
Muscle invasive Cancer 13/14* 13/16 0.08 1.96      
* Three unavailable
Table 5.1: Staining Characteristics based on tumorstaging
To compare the Ki-67p and Ki-67d indices, these were further grouped into
the four ranges (0-0.1[1], 0.1-1[2], 1-2[3], 2+[4]). Using Spearman’stest(15)
there was a significant agreement betweenthe indices used in comparison to
the baseline scores (Ki-67p r, =0.75, Ki-67d r, =0.52). Ki-67p and Ki-67d
were in almost total agreement (+ 1) with the corresponding baseline score
in 92% and 70% oftheslides, respectively. The proliferation rates measured
by Ki-67p and Ki-67d revealed a steady increase with stage. However, there
wasa decline in proliferation rate as some tumors becameinvasive (Figure
5.5 and 5.6). This was not evident with grading, worsening grade being
associated with increased proliferation.
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Figure 5.5: Muscle-invasive (Grade II, pT2) bladder cancer with low-to-moderate
cancercell proliferation (Group 3). Proliferating cells are predominantly observed
within the lymphocytic component. (magnification x240)
 
  
Figure 5.6: Muscle-invasive (Grade II, pT) bladder cancer with high cell
proliferation (Group 3). (magnification x240)
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Morethan two index readings wereavailable for 10 patients to analyse
disease progression (Table 5.2). Mean follow-up in these patients was 3.6
years (range: 6-132 months). Three of these 10 patients showed disease
progression. Nocorrelation wasidentified between the proliferation indices
and disease progression. However,in this small group within the study
population, a higher initial Ki-67 index indicated an unstable tumor-cell
population. In the six patients with initial Ki-67d >0.005, Ki-67p >0.3
disease progression occurredin four (italics) and downstaging of their
cancer occurred in two (bold). The two in whichtheir disease was down-
staged had markedly highinitial proliferation indices (Ki-67d>0.2, Ki-
67p>4) while the four in which their disease progressed exhibited only
moderately elevated indices (Ki-67d=0.005-0.03, Ki-67p=0.4-2.2). The
disease wasclinically non-progressive in four patients with lower tumor
indices (Ki-67d<0.005, Ki-67p<0.1).
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P INITIAL SCORES FINAL SCORES
"Rr. OLL BAS PRO
nj OW DIAG BASE] K167| K167 DIAGN ELIN| K167| K167| GRES
o| YR NOSIS} LINE} D P YR|  OSIS E D P Ss(YRS)
G2p G2pT
1} 3 99 T1 3 .215| 61} 02 a 2 .246| 1.63) No
G2p No
2| 0.5 02 Ta 1 004} 0.1 02} G2pTa} 2 .375] 8.6
G2p Yes
3} 2 00 Ta 3 .007| 0.35| 02 G3pTI| 3 .051} 2.09
G2p
4) Il 91 Ta 2 .005| 1.34| 02} G3pTI| 3 1.02| 15.3] Yes
G3p G3pT
5} 5 96 T2 2 0 0 Ol 1 3 0 0.12} No
0.00
6| J O01 CIS 2 .03 2.16| 02| G3pT1| 2 8 0.6 Yes
G2p
7} 2 97 Ta 3 .188| 4.27} 99] Dys 2 .021| 0.21) No
G2p G3pT
8| 4 98 T2 2 0 0 02 2 2 .017| 0.74} No
G3p
9| 7 95 Tl 1 .002| 0.01} 02 Infl 1 .003} 0.04} No
1 G3p
O} 0.5 01 Tl 2 .034| 1.47| 01 G3pT3| 2 .011| 0.6] Yes  
Table 5.2: Progression and mean Ki-67 expression in 10 patients with more
than two index biopsy specimens
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5.7: Discussion
Ki-67 expression has been widely used to determinecellular proliferation
rates in a range of malignanttissues and it has been shownto be an
independentpredictor of disease progression in the prostate °°8 and in
proliferative breast disease °67 Other studies have confirmed a correlation
between Ki-67 expression and bladder tumorstage and grade 269-272We
haverefined the analysis of tumor-cell proliferation in bladder neoplasia to
define two new indices: Ki-67percent (Ki-67p) and Ki-67density (Ki-67d)
that have been used to develop a semi-automated analysis of these
parameters. In accordancewith similar studies analysing Ki-67, we have
demonstrated a correlation between Ki-67p and Ki-67d with tumorstage
and grade. Studies on recurrence and Ki-67 indices suggested a higher
2 -273 ;69 271-273 and worse survivallabelling index in those with recurrent disease
°74 Although ourstudy wasunable to identify a relationship between Ki-67
expression and tumorrecurrence, we showed significant decline in cell
proliferation rate in some tumors with progression to muscle invasive
disease (pT;— pT>transition). In a small subset, tumors with higher initial
proliferation indices comprised a behaviorally unstable cell population with
either progression or down-staging of disease. These tumorsalso tended to
reduce Ki-67 expression over time. Lowerinitial Ki-67 indices were
associated withstatic or indolent disease. The biological significance of
these observationsis that while low cell proliferation, identified by low Ki-
67 expression, may indicate phenotypic indolence, very high Ki-67 levels
signify genetic instability that, in other carcinomas maybeassociated with
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275276Tt is possible that these cells are biologicallygoodclinical prognosis
incompetent and hence unableto survive or to progress to malignant
neoplasms.
A cellular phenotype is the vectorial consequence of a numberof constraints
(gene expression, epigenetics, epithelial-stromal cross-talk etc.) that interact
to producecells with features that are collectively characteristic in
appearance and behavior °17These are complexinteractions between
numerousprocessesthat span several scalesof time, involve a variety of
componentsand are also determined by environmental location. This com-
plexity has generated contrasting views on fluctuations in levels of gene
expression andof their corresponding protein products 778279Consequently,
the phenotypeof an individual cell, whether benign or malignant, is not
static but potentially changing occurring wheneveroneof the constraints
becomes modified. Simultaneous comparative gene-expression monitoring
has been usedto identify functional groups of genes whosepatterns of co-
regulation has providedthe basis for separating bladder tumors according to
microanatomical location **°. That study revealed particular gene-
expression profiles to characterize each pathological stage, suggesting the
phenotype-modulating effects of environment. This current study has
shownthat proliferation of cells within individual urothelial cancers to be
influenced by the environmental location, whetherin the lamina propria
(pT,) or in smooth muscle (pT2). These observations havesignificant
implications for current concepts of the malignant phenotype, especially
whenunderstanding of the modeof action of therapeutic agents and the
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consequencesoftheir use. Thus, the steady state of a population of cells
dependsupontheinteraction of several complex variables that include, inter
alia, the rate of cell proliferation promoting expansion andthe rate of
apoptosis retarding expansion of that population as well as the metabolic
competenceofthose cells (e.g. aerobic vs anaerobic respiration) with
respect to constraints pertaining within the local environmentatthe time.It
is not only gene expression that predicates the activity or competence of a
cell but the relative amounts of protein translated from its transcribed
mRNAandthereafter modulated by epigenetic factors. Our previousstudies
*81-283 emphasized a functionalrelationship betweenof estrogen receptors
these proteins suchthat their ratio provides the regulatory control, rather
than their absolute levels. While superficial bladder carcinomas with a low
initial rate of cell proliferation may benefit from delayed chemotherapeutic
modulation, a very high level of Ki-67 expression might indicate a possible
unstablecell population with an ineffective impact on tumor progression
and consequently a comparatively better prognosis than those with moderate
cell proliferation.
The semi-automated system described in this study has enabled Ki-67
analysis produces objective and quantifiable data of greater accuracy than
can be obtained subjectively. Significant correlation wasidentified between
the baseline scores obtained subjectively and the semi-automated numerical
indices. This study reported a better agreement between Ki-67p and baseline
scores in comparison with the Ki-67d than could be explained by an
observer analysingthe entire field rather than restricting observationsto the
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carcinomafields only. Conversely, fully automated image analysisis not
currently able to distinguish between morphologically different areas, such
as invasive cancers and stromaltissues. Therefore, any automated technique
currently requires at least some level of operator guidance,at least to enable
recognitionofthe field to be analysed, and an informed understanding of
each tissue being assessed is currently necessary. Experienced operators are
able to integrate, at a subliminal level, areas of importance that a computer
is unable to distinguish. Nevertheless, computer-based image analysis
provides objective numerical data available for comparative studies between
serial biopsies overtime, or with other parameters, such as expression of
cell-cycle checkpointproteins, to provide a robust assessmentof the
biological competenceor progression of an individual bladder cancer.
In conclusion, the two parameters of Ki-67p and Ki-67d as definedin this
study, correlate well statistically in bladder cancer. An increase in these
indices correlated (p<0.001) with both tumor grade and invasion. There was
also a significant agreement betweenthe indices and baseline scores.
Patients with initial low proliferation rates showedstable disease while
moderately increased indices were associated with disease progression.
However, those exhibiting very high initial proliferation indices appeared
unstable with respect to risk of progression with some diseases appearing to
undergo regression. As those tumours became muscle invasive (pT;— pT2
transition), proliferation indices declined. This observation could be
explained by tissues with higher cellular proliferation rates having different
biological and pathological constraints in locations whereidentical
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regulatory criteria may not apply. Computer-assisted image analysis to
quantify maximum cell proliferation according to Ki-67 expression in
diagnostic biopsy specimensis a more accurate predictor of bladder cancer
progression that could be employed routinely as one of the core parameters
to determine individual bladder cancer management.
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Chapter6:
Biomarkerexpression pattern in Benign Urothelium
and Non-Muscle Invasive Urothelial Carcinoma
138
A diagnosis of urothelial carcinomais associated with a significant
morbidity to the patient as well as a need for long term surveillance. In
addition to the economic burden,this diagnosis often presents a therapeutic
conundrum for the clinician. Approximately 80% of the newly diagnosed
urothelial carcinomapresent with non-muscle invasive or superficial
carcinoma'®>. Patients with diagnosed urothelial carcinomaaretreated with
transurethral resection of the tumour. These often respond to further
treatment with adjuvant chemotherapy or immunotherapy. Therisk of
'85 Further need for treatment dependsrecurrencein these patients is 70%
on the cystoscopic surveillance findings and histopathological staging;if
recurrences occur. Despite an array of prognostic factors ranging from
tumoursize, primary stage and grade, to molecular analysis; the ability to
assess and predict disease progression isstill ambiguous.
Malignant transformation of normalcells occur either through expression of
new genes(oncogenes)orthe loss of the regulatory genes (tumour
suppressor genes)". The ability to detect cancer cells early and predict the
nature and aggressiveness of the tumour populationis limited at present to
routine histopathological analysis. The optimal management requires the
accurate assessmentof the tumourbiologic potential whichis not entirely
possible with just histological determination. Recent changesin the
assessmentand treatment of non-muscle invasive urothelial carcinoma has
been based on categorizing this disease based on the variousbiological
forms. This was conceptualized because apparently homogenousformsof
non-muscle invasive urothelial cancer seem to behavedifferently in
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responseto treatment, suggesting that histologically similar disease might
actually have different biological pathways.
6.2: Cell Cycle Regulatory Proteins
Studies have lookedat alterations and aberrations in molecular pathways
which govern urothelial tumourigenesis. Normal cellular proliferation
occurs by a systematic progression throughthe variousstagesof the cell
cycle, which also is the most commonsite of biomarkeralteration in human
urothelial carcinoma. The character of the cell is defined by how it responds
to cellular stresses such as DNA damage. DNA damagecan be purgedeither
*85 There is a consequentby DNArepairorbythe initiation of apoptosis
decreasedrisk of uncontrolled excess of abnormal cells and therefore a
reducedrisk of cancer formation. Deregulation of these cell-cycle control
mechanisms is a commonoccurrence in malignant tissue transformation.
Thecell-cycle associated markers that have been analyzed in this work have
been the G,/ S phasetransition modulators p53, p2i™"", p16 and Rb.
Cellular proliferation markers such as Ki-67, proliferating cell nuclear
antigen (PCNA)**°, cell adhesion complex protein (a-catenin)**’ have been
studied as prognostic markers in bladder cancer. Thepredictive value of the
most promising markerin this group is Ki-67 which has been discussed
separately in Chapter5.
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Figure 6.1: p16, p21, p27 and p53inhibit the cell cycle by acting on the
cyclin-dependant kinases
6.2.1: p53 protein
p53 tumoursuppressor gene isolated to the chromosome 17p13,hasa vital
role in cell cycle regulation”®®, It is presumedthat the wild type p53 may
activate the transcription of inhibitory genes including down-regulation of
the cell cycle and suppressionofthe initiation of DNA replication” 289-290
p53 is more involved in regulating and controlling the cell-cycle than in
playing a direct role in the mechanism of cell cycle progression”7! p53
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mutations are the most common genetic alteration in malignancy”. This
results in altered protein products with longerlife compared to the wild
type; accumulatesin the cell with increased expression levels detected on
immunohistochemicalstaining. It is an important prognostic factor for
139293 294 with p53 accumulation associated withbladder cancer progression
increased grade and stage of cancer, and poorclinical outcome”, In this
study cohort, there was a highly significant gradation in p53 expression
betweenthe controls, early superficial disease and pT1 urothelial carcinoma.
However,the data available regarding the role of p53 as a prognostic
indicator in patients with non-muscle invasive tumours has been
oye 4conflicting'*! 300 |
Zlotta et al.'*? showedsignificant p53 expression correlation with stage in
superficial bladder cancer. Our study also revealed similar correlation in
L.'*' studied a cohortnon-muscle invasive carcinoma (Figure 6.2). Sarkis et a
of 43 patients with non-muscle invasive urothelial carcinoma; reporting
tumour progression in 76% of the patients with >20% p53 expression while
only 17% with <20% expression developing tumourprogression. A strong
p53 staining showedsignificant correlation with muscle invasive behavior
and poorclinical outcome. In this study cohort, over 70% of patients who
had progressionto invasive disease had high initial p53 expression. Esrig et
al.'*? found that patients with urinary bladder confined disease with p53-
negative tumours tend to have a low rate of progression. However, they did
not feel that this correlation was as robustas reported and suggested that the
nuclear accumulation of p53 could occur in the absence of p53 gene
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mutations. The p53 gene mutationor lack of in the presence of
immunohistochemical detection of p53 protein could explain the disparity in
assessing the prognostic benefit of p53 in urothelial cancer. Later studies
have confirmed that p53 does have an importantrole as a biomarker” *°”,
Studies on p53 have found high levels of immune-reactivity in tumours with
high propensity to recurr’”’ *°°, Moreover, some studies report an association
between p53 over-expression and tumourrecurrence also in non-muscle
invasive disease!*® 3% 3°,
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Figure 6.2: p53 expression (%) by tumourstage.
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Figure 6.3: p21 expression levels (%) by tumourstage.
MI-muscle invasive carcinoma
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6.2.2: p21 protein (WAFI/CIP1 gene)
p21 is a 21kD protein encoded by the WAFI1/CIP1 gene.It is a potent
inhibitor of cyclin dependant kinases which havea significantrole at the
G1-Stransition for cell-cycle progression (Figure 6.1) thereby controlling
cell proliferation and the ability to impede DNA replication?”°°”. It
interacts with cytoplasmic proteins in cellular response to DNA damage and
also has a role in cellular protection against apoptosis. p21 is a p53
downstream mediatorofthe antiproliferative function of the wild-type
psa. Theability of p53 to control the cell cycle is related to the ability of
p53 to activate genes such as p21 '29' Studies'®*°8 have shownthat p53
exerts its effects on the cell cycle through controlling p21WArverh
expression. p53 alterations lead to loss of p21 protein expression leading to
unregulated cell growth. The overall positive rate was 25% with 28%
positivity in non-muscle invasive disease.
Stein et al.'*° reported the strongest association between p21 status and
tumourprogression in patients with organ confined disease ( <pT3a). Loss
of p21 expression wasstrongly associated with increased probability of
recurrence anddecreased survival'®°. Despite p53 being a significant brake-
pointin the cell cycle, maintenance of p21 helps protect cells from the
detrimental effects of p53 alterations'~*. This could be becausethe effects of
p21 onthe cell-cycle maybe through p53 independent pathways!** 'They
also opinethat patients with tumoursthat have altered p53 and lost p21 have
a poorer prognosis. However, we were unable to show anysignificant
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association between tumour stage and p21 expression. In this study cohort,
there was a markedincrease in p21 expression within dysplasia, CIS, pTa
disease. Loss of p21 expression was seen in pT1 stage. Based on ourdata,
we foundpreservation of p21 expression in early NMI. Loss of p21 reflects
worsening grade over pT1 disease and muscle invasive disease (Figure 6.3)
In the normal controls, there was low p21 expression suggesting that the
increased p21 expression suggests malignant transformation. This agrees
with Korkolopoulouet al. who reported expression of p21 early on in
tumourigenesis*”. However,in our cohort, presence of established
urothelial carcinoma,loss of p21 implies aggressive tumour; which suggests
that non-muscle invasive and muscle invasive urothelial cancer could be
two differing disease entities.
6.2.3: Rb protein (Retinoblastoma gene)
Rb protein in the hypophosphorylated state acts as a tumour suppressor
inhibiting cell cycle progression at the G,/Srestriction point. Accumulation
of the hypo-phosphorylated pRb blocks E2F dependanttranscription leading
to cell-cycle arrest’. Phosphorylation of pRb rendersit active; activating
factors like cyclins which increasecellular proliferation rates. Alteration of
the Rb gene expression has been foundin different types of tumours
including bladder carcinoma'“*?!°. Hypophosphorylated Rb acts at the G1-S
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check point binding to a numberofcellular proteins including E2F (a
$1131? thereby inhibiting cell-cycle progression.transcription factor)
Rb geneinactivation is thoughtto bea critical step in bladder cancer
progression'* . Kubotaet al.?"° suggest that Rb loss is involved in tumour
initiation. In this study cohort, despite not reaching significance, there
occurred Rb loss in non-muscle invasive urothelial carcinoma. Most studies
have reported dual inactivation of p53 and pRb suggesting that this occurs
in oncogenesis because pRb deficiencyresults in uncontrolled cellular
proliferation; which with defective p53 does notresult in apoptosis!“ 315.
Studies havealso reported a role for p16 as a modulator for Rb expression
31levels*!®.
6.2.4: p16 protein (CDKN2a gene)
The gene for p16 (CDKN2a)is located on the 9p21 gene.It is a crucial
inhibitor of the cyclin-dependant kinase complexandit is inactivated to
permit progression through the G1/S cell-cycle check points~”’ °28 Up-
regulation ofthe cell cycling occurs with the loss of p16 function and
subsequentloss of Rb tumour suppressor function””’*”’, Santoset al.?!”
suggested that the loss of p16 staining is an early genetic event in bladder
carcinogenesis. It has been reported to be more commonin pT1 than in
i : : 31 : ‘ jmuscle invasive disease''’ *'®. This loss of protein expression was not
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. : . . ;. 9associated with an increased risk of recurrence or progression 45317.
However, other studies have reported variable results???"
1.°** studied p16 expression analysis finding weak expressionNakazawaet a
in non-neoplastic lesions. They also found a higher incidence of p16 over-
expression in non-infiltrating urothelial carcinoma. Our study showed low
levels of expression in normalcells; significant increased expression in non-
muscle invasive carcinoma in comparison to the benign bladdertissue.
There were similar levels of high expression between the early superficial
NMIcarcinomagroup (dysplasia, CIS and pTa disease) and pT1 urothelial
carcinoma.
The variable reports could be explained by some degree of cytoplasmic
staining in all p16 positive cells'*'. This background cytoplasmic staining
wasconsidered normal p16 staining as it was seen only in the tumourcells,
considered specific for p16.
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6.3: Apoptosis regulators
There are several noxious stimuli which initiate and propagate the process
of cellular death. This is brought about by the disruption of the dynamic
equilibrium between apoptotic cell death and cell survival by alterations in
gene products regulating cell survival such as p53 (discussed earlier), Bcl-2
and other homologuesof the bcl-2 family such as Bax? **4 and bel-X’””.
The apoptotic process is initiated by pathways involving either the
activation of death receptors on the cell surface (extrinsic pathway) or
mediated by mitochondria (intrinsic pathway)’. The final common
pathwayleadsto the activation of cysteine caspasesthat initiate andeffect
5 3irreversible cellular changes””’.
6.3.1: Bel-2 protein
The bcl-2 protooncogeneanti-apoptotic action is by regulating a
downstream eventin a final common pathwayleading to apoptotic cell
h*°8. The bel-2 protein is involvedin the intrinsic pathwayandcontrolsdeat
mitochondrial membrane permeability and inhibits caspase activation®”’.
Increased Bcl-2 expression has been associated with decreased tumour-free
survival in G3pT1 disease*”®. In this study cohort of 301 index bladder
biopsies, there was significant loss of bcl-2 expression in the non-muscle
invasive cancers (Figure 6.4), both pTa and pT1 disease with no significant
difference between these two groups. In total, there were only 14 Bcl-2
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positive specimens (8%) from total of 186 index bladder biopsies with
199 327bladder malignancy (Table 6.1). Other studies also report similar low
Bcl-2 (5%-7%) detection rates in urothelial transitional cell carcinoma.
 
 
Grade & Stage Positive staining (n) % of cases
Normal 11 65%
Chronic Inflammation/ NAD* 25 33%
Dysplasia — G)pTa 10 14%
G2pTa 1 2%
G1/2pT1 1 5%
G3pTa 0 0%
G3pT1 2 7%    *NAD-Noabnormality detected
Table 6.1: Percentage Bcl-2 expression by Grade and Stage
Sub-group analysis of the cancer group did not show anyvariation in the
very low Bcl-2 expression levels in histological malignant bladdertissue.
Only 8% of pTa (including dysplasia and CIS) tumours and 6% of pT)
tumourshad positive Bcl-2 expression. Therefore, I could not opine on the
suggestion that persistence of Bcl-2 expression in bladder malignancy
implied better prognosis in various stages of bladder malignancy*8
In this study, there are higherlevels of bcl-2 expression within the true
normals (65%) and in the inflammatory biopsies (33%). This is in contrast
to published literature where the expression in “normalurothelial cells” has
also been reported to be low!” **7. However, the histological normaltissue
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considered as controls in these studies were either from patients with cancer
(renal and bladder)!” or not described *””. I do not feel these tissue samples
are biologically normal urothelium and suggest that these have differing
biological characteristics in comparison to normalurothelial tissue from
patients with nosuspicion or history of urothelial malignancy.Thisis
discussed later in Section 6.9.
In contrast, malignant urothelium had low bcl-2 expression (0-14%)
suggesting an association of bcl-2 loss with tumourigenesis. Extrapolating
these findings imply that sparing of bcl-2 expression in malignanttissue
could be of prognostic benefit. The evidence is far from robustin this regard
and needsfurther studies into the genetic background andthe role of other
tumour markers in bladder cancer apoptosis.
6.3.2: Bel-Xz
Bcl-X is an anti-apoptotic gene, a homologueof the bcl-2 gene family.It
demonstrated different expression patterns and wasthoughtto regulate cell
cycle at different stages of cell differentiation than bel-2'*’. Bel-X encodes
for two proteins. Bcl-X_,is the longerprotein transcript of bcl-X gene
suppressing cell death with the shorter bcl-X; promoting apoptosis~”’.
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Bcl-X has been shownto be over-expressed in malignant bladder neoplasms
3°Tn our study cohort, normal urotheliumand correlated with stage
expressed very low levels of bcl-X, which continued to be maintained in the
early carcinoma. pT; disease is associated with marked over-expression. We
had smaller numbers of bcl-X, which could explain whythe data did not
reachstatistical significance.
6.4: ErbB-2 Oncogene
This oncogeneis located on chromosome 17q21, a memberof the human
epidermal growth factor receptor family”. ErbB-2 (Figure 6.5) protein has
an intra- and extra-cellular domain with tyrosine kinase activity involved in
33152 Amplification of the gene has beensignal transduction of cell growth
reported in over 30% of womenwith breast cancer with consequentprotein
receptor over-expression; significantly associated with tumour
aggressiveness and poor survival*** 334, It has also been describedin other
solid tumours suchas colon, lung, ovary, stomach and thyroid** .
In bladder cancer, erbb-2 amplification has been associated with almost
20% of the advanced and high-grade tumours**°; a very frequent
amplification in bladder cancer. Increased erbB-2 expressionin bladder
. 337 .cancerhas been foundto correlate with tumourrecurrence”””, aggressive
338 ] 339stage’, and poorprognosis”. Lipponenet a suggested an association
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of moderate/ severe erbb-2 over-expression with a more aggressive tumour
type. However, in low malignant potential papillary tumours, studies have
shownnocorrelation between protein expression and stage or grade*™
whichis in compatible with our results. In our cohort, there was no
difference in erbb-2 expression levels between normal urothelium and NMI.
Erbb-2 does not appear to havea role in early urothelial cancer.
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Figure 6.4: Bcl-2 expressionloss in urothelial carcinoma
 
Figure 6.5: erbB-2 expression in normal bladder urothelium
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6.5: PTEN tumoursuppressor gene
This tumour suppressor gene mappedto the 10q locus has been suggested to
play role urothelial cancer’. PTEN mutations have beenidentified in
*41 andin the urinaryvarious cancers” including prostate carcinoma
bladder”** **. Wang et al.*"° suggest that loss of PTEN expression could be
a late event in bladder cancer. Wedid notfind any significant variation
betweenthe urothelial tumour stages or the benign group.
6.6: Oestrogen Receptors:
ER a and ERf are the two major oestrogen receptor subtypes which
modulate the effect of oestrogen oncell proliferation and survival.It is
especially important in tumour-prone tissues which are responsive to
hormonessuch asthe uterus and breast*“’ which have higher receptor levels.
Studies have shownover-expression of ER a in breast cancer with down
regulation of ER p°“434°_ ER B over expression resulted in reducedcell
proliferation and with a concomitantstunting of the cell-cycle*44345 Based
on these studies, Helguero et al.**> raised the hypothesis that ER B has a
significantrole in inhibiting ER a activity and the loss of ER B is associated
with the developmentof cancer®*>.
Moststudies on oestrogen receptors in urothelial cancer have reported ER B
expression loss with malignant changeresulting in an increased ER o /ER B
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ration", High levels of ER a have been foundin a large numberof
humanbladder cancers”. Tengetal.”“8 also found significantly higher
levels of ER a in malignant urothelial cells but with similar levels of ER B
expression within both tumour and normal cells.
In this study cohort,all tissue showed no ER a expression, neither in benign
urothelial tissue nor in different stages of urothelial NMI carcinoma.
However, normal urothelium showeda high ER £ expression (42%) with
subsequentloss in carcinogenesis with levels dropping to 20% (Table 6.2).
This study lends credence to the Helguero hypothesis*°The results suggest
that it is probably the ER B receptor that plays a majorrole in urothelial
carcinomaand not the ER-a receptor as reportedsofar.
 Benign Dysplasia, pT1
urothelium CIS, pTa disease
 
ER a* n 2 67 24
% 0 0 0
ER B n 19 123 50
% 42 21 20       * all ER a stained tissue were negative
Table 6.2: Oestrogen receptor expression Vs tumourstage
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6.7: Heat-shock protein 27 (hsp-27)
Heat shock proteins (HSPs) are highly conserved chaperoneproteins
expressedin cells usually in response to stress. Expression levels are often
increased in a wide range of cancers. In this family, hsp-27 is a cytoplasmic
protein which is present within normal and malignantcells. It wasinitially
discovered as an oestrogen-modulated protein in breast cancer*”” and then
found to contribute to apoptosis*>e . Hsp-27 over-modulation has been shown
to be predictive of death from prostate cancer*>', subsequent developmentof
breast malignancy from early proliferative breast lesions*” and associated
with grade in cervical neoplasia*8
In this study, 254 index bladder specimen stained with hsp-27 were
available for assessment with very high levels of (>85%) positive
expression seen.
 Benign Dysplasia, pT 1
urothelium CIS, pTa disease
Hsp-27 n 13 94 47
 % be 90 87       
Table 6.3: Extent of Hsp-27 expression Vs tumourstage
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The only similar study in literature showedno significance in bladder
cancer™. However, there occurred positive staining within the lamina
propriae of histologically pTa tumoursraising the possibility that these
biopsies are showingsigns of early lamina propriae invasion (Figure 6.6).
However, the numbers were too small for meaningful analysis but could
play a role in assessing stage migration.
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6.8: Flat (Pre-) neoplastic lesions
Oneof the caveats of this study is the grouping of three disease entities
under one umbrella. Dysplasia, carcinoma-insitu and pTa tumour were
grouped together for analysis purposes. The molecular biology of these
groups are similar but probablynot identical. The histopathological
diagnosis of these three entities is difficult with significant variability
among histopathologists regarding whatconstitutes a particular diagnosis.
This is because in dysplasia, the degree of architectural frailty is not as
prominentas seen in carcinomain-situ and even more so in pTa disease;
despite sharing many similar morphological and genetic features. The
cellular changes include marked nuclear enlargement, nuclear
hyperchromasia, increased nuclear/ cytoplasmic ratio and somenucleolar
abnormailities. Inter-observer variation and the lack of uniform definition
have madedifferential reporting especially of dysplasia and carcinoma
insitu difficult and often confusing. The same problemspersist in the
diagnosis of pTa disease.
Urothelial neoplasmsare multifocal with a high rate of recurrence. The
latest theory on urothelial carcinogenesis is the field defect theory
suggesting that triggers effect genetically altered cells which become the
source of polyclonal tumours''' *°, Hodgeset al.*°° postulate that based on
the molecular alterations, that flat urothelial lesions comprise a wide
morphological spectrum from reactive atypia to carcinomainsitu.
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6.9: No abnormality detected/ Inflammation with no atypia
Molecular studies have suggested instability in normal urothelium in
bladders with knownora history of urothelial carcinoma’. This again
supports the conceptof field changes in bladder urothelial cancer. In our
study cohort (Figure 6.7), there were significant differences in bcl-2
(p=0.017), PTEN (p=0.024) and in erBB-2 (p=0.011) expression levels
between the two groups, true normal and those with no histological
abnormality but with a history of urothelial malignancy. Studies which use
histologically benign urothelial tissue as control do not take into account
these potential field changes confoundingresults. This study cohort offers
evidence suggesting that patients with a history of urothelial neoplasia
would always have a degree of urothelial instability and should not be
considered to be normal. However, the molecular pathwaysin this distinct
sub-group (histologically normal/ biomarker abnormal) need to be
understood as probably a separate pathway and should notjust beattributed
to urothelial carcinogenesis associated field changes.
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Figure 6.6: Clusters of invasive urothelial carcinoma within submucosa
identified by strong Hsp-27 expression (Discriminating pTa from pT 1)
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Figure 6.7: Biomarkervariation between Normal urothelium and other non-
malignant urothelium (inflammation/ history of urothelial malignancy)
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Chapter 7:
Biomarkerexpression pattern in
Muscle Invasive Urothelial Carcinoma
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The majority of patients with urothelial carcinoma have a non-muscle
invasive tumour (pTa-pT| stage) at diagnosis. However, between 10% and
30% of the patients diagnosed with urothelial carcinoma have muscle
invasive disease at diagnosis! '°70% of the patients with non-muscle
invasive tumourrecurafterintial resection, and upto fifth of these patients
develop invasive urothelial carcinoma ''9Urothelial carcinomapatients
with muscle invasive disease (>pT>) are at higher risks of recurrence and
subsequent death from the disease. Treatmenthas to be aggressive;this is
either surgery in the form of radical cystectomy for T2, T3 stages of the
disease or chemotherapy/ radiotherapy in more advanced disease such as T4
urothelial carcinoma, nodal or metastatic disease. Despite aggressive
treatment, these patients have a high morbidity and mortality. Conventional
histopathological assessmentdoesnot accurately predict the behaviorof the
urothelial carcinoma. Therefore, the therapeutic protocols have now
centered on the needto identify the subset of urothelial carcinomapatients
whoare likely to progress, also those with a high propensity to recur and the
tumours which could beresistant/ respond poorly to local treatment.
Indirect epidemiological evidence indicates that only a small number of
patients with invasive cancer had a history of non-muscle invasive
carcinoma’ *°*, However, Volante et al.*”” suggest that progression of
urothelial carcinoma can occur from non-muscle invasive (superficial) to
muscle-invasive urothelial carcinoma through accumulated genetic
alterations. This is the most important challenge as the patients who develop
muscle invasive tumour from primary non-muscle invasive tumourfare
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worse than patients who have had a primary diagnosis of muscle invasive
tumour *’. Scientists have attempted to define tumourigenesis pathways so
as to better understand urothelial carcinoma with the development of
moderntechnologies such as immunohistochemistry. However, the process
of malignant transformation of urothelium has been associated with various
molecular pathways; the identification of which will help identify
prognostic pathway-specific signatures. In this chapter, the focusis limited
to the developmentand transformation to muscle-invasive urothelial
carcinoma whichI havetried to characterize with the help of the panel of
markers. The significant markers involved in the developmentof/
transformation to muscle invasive tumourare discussed below.
7.1: Cell Cycle Regulatory Proteins:
Cell-cycle regulators are the most studied of the various biomarker groups
in the developmentof muscle invasive urothelial tumour. Unregulated
cellular proliferation is a cardinal dysfunction in carcinomatous
transformation of urothelial cells. The normal cell-cycle is controlled by
variouscell cycle check-point regulators such as p53, Rb, p21 and p16.In
this chapter, we report the salient biomarkers that have shownto be
significant in the diagnosis of muscle invasiveurothelial tumourorthe
progression to muscle invasive urothelial tumour.
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7.1.1: p53
The prognostic value of p53 in muscle invasive urothelial tumour has been
studied by various groups. Esrig et al'8° evaluated more than 250patients
who underwentradical cystectomy. They reported that p53 over-expression
wasassociated with higherrisk of disease progression and reducedoverall
survival irrespective of stage. They felt that p53 could influence selection of
patients for adjuvant treatment. Patients with p53- positive urothelial
carcinomaincluding those with superficially invasive disease have been
reported to have a poor prognosis” '41 Sarkis et al.'*' reported poorclinical
outcome(muscle invasive behavior) with strong p53 expression in a cohort
of non-muscle invasive tumourpatients. This study cohort also showed a
markedloss in p53 expression in the muscle invasive cancer but with no
prognostic significance associated with p53 expression. This is in agreement
with Drageret al.**'in their metaanalysis reporting no prognostic benefit
with p53 in muscle invasive urothelial tumour.
The data suggeststhat there is a double-hit mechanism in the p53 associated
tumourigenesis. This study showslow levels of expression in the controls
with significant differential p53 positivity with non-muscle invasive disease
and moreso in pT; disease. Tiguert et al.*©* have also reported on the value
of p53 immunostaining in predicting progression in T; disease. I foundthat
the comparative p53 expressionis less in muscle invasive disease
suggesting that there is a second event with late loss of p53 implying a
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poorer prognosis and aggressive character in agreement with the studies
discussed above.
Studies havealso assessed the effect of intravesical immunotherapy with
Bacillus Calmette-Guerin (BCG). p53 negativity has been provento herald
progression in patients with recurrent tumours whohavefailed BCG
363Wehavenotbeen able to analyze the effect of intravesicaltreatment
chemotherapy/ immunotherapy as the numberof patients who had
undergonethese treatments was small.
7.1.2: pRb (retinoblastoma gene)
Rb inactivation is considereda critical step in urothelial tumour progression.
Rb susceptibility gene acts as a negative cell-cycle regulator by sequestering
membersof the E2F family of transcription factors which repress apoptosis.
Studies have shownthat higher grade and stage bladder tumours exhibit
more Rbalterations'’**™. Rb loss was significantly associated with shorter
five year survival'*® '*? in muscle invasive urothelial tumour compared to
those who maintained Rb expression. However, other studies have failed to
show a correlation between low pRbstaining and recurrence or
progression”’ 'S2In this cohort, there was a no significant difference
betweenthe levels of Rb expression once malignant change had been
established. Moreover, alterations in p53 and pRb mayactin a synergistic
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7 «3 ¢. 8 :fashion to promote tumour progression 6° This is commoninlocally
advancedurothelial tumourand has a poor prognosis ’*”
Rb —-*E2Fl ———> pl4/ARF ——* Hdm2 ——»{>_ Atk|
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Figure 7.1: Cross talk between signaling pathways. Rb, p53 and PTEN*®
7.1.3: p21
In this study cohort of 220 index bladder biopsies, p21 immuno-positivity
occurred in 25% (55 patients) of the bladder tumours with 32% (6 patients)
positivity in muscle invasive tumours.Thisis similar to published literature
which report rates of 33% and 64% positivity!” 367368 Moststudies on p21
expression have studied it in tandem with p53. Stein et al. evaluated 101
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patients who underwentradical cystectomy for invasive bladder carcinoma
and reported significantly increased probability of recurrence and
significantly reduced overall survival'””. In this study, p21 was the only
independentpredictor of disease progression in men with bladder tumours
that had altered p53. Stein et al. suggests that patients with p53 altered
tumoursthat loose p21 expression have a poor prognosis and should be
considered for adjuvant treatment'””. I did notfind a significant difference
in p21 expression levels based on stage. However, despite no correlation,
32% of the muscle invasive tumours were positive for p21 expression
comparedto only 16% in the normaltissue suggesting that p21 positivity
might be associated with tumourigenesis. Figure 7.1 showsa possible
pathway for p21 (interchangeable with p27).
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Figure 7.2: p 16 expression in muscle-invasive urothelial carcinoma
 
Figure 7.3: p 21 expression in muscle-invasive urothelial carcinoma
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7.2: Apoptosis modulators
Apoptotic cell death is as importantas cellular proliferation in maintaining a
dynamic equilibrium. Therefore the effect of apoptotic markers also play an
importantrole in the diagnosis, recurrence and progression of urothelial
carcinoma.
7.2.1: Bel-2 and Bel-X;,
Bcl-2 protein hasthe ability to block apoptosis and the wild-type function of
the p53 gene. We foundhighlevels of bcl-2 expression in normaltissue.
Uniform loss of expression was seen throughall stages of urothelial cancer
through to muscle invasive urothelial tumour. Glicket al.*°? found that only
24% of the invasive bladder tumours expressed Bcl-2 protein. There was a
significant correlation with Bcl-2 absence andstage.
Bcl-X, mediated micro-environmental signals have been reported in B-cell
leukemia to reducesensitivity to chemotherapy*”°. Howeverthe expression
levels were very low in the bladder biopsies in our study thereby failing to
199enable any meaningful assessment. In contrast to Kirsh et al. *”, we found
that muscle invasive tumourhad significant over expression of Bcl-X_,,
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Benign Non muscle invasive Muscle invasive
urothelium Tumour Tumour
Bcl-2 n 17 182 a
% 65% 8% 71%
Bcl-X, n 2 82 12
% 0% 4% 25%       
Table 7.1: Extent of Bcl2 & Bcl- X, expression Vs tumourstage
7.3: Oncogenes: erbB-2
erbB-2 is one of the most frequently amplified oncogenesin urothelial
cancer. In urothelial cancer, it predominantly is expressed in advanced and
high-grade tumours**°. The expression of erbB-2 in muscle invasive
urothelial carcinomahas been reported to range between 23% and 80%?”
371-373 We had similar results with over expression in 62% ofthese cases.
erbB-2 expression has been reported to be associated with worsening
338374375 erbB-2 levels were high in the33 ;stage ® and decreased survival
normalbladdertissue (90%) which was maintained in non-muscle invasive
urothelial carcinoma with over-expression levels of 84% . However,there
was a Significant loss of erbB-2 with tumourinvasion.
Moststudies on erbB-2°*? ”°*”” have reported similar results suggesting that
anti-erbB-2 treatment may havea role in muscle invasive urothelial
carcinoma. Bolenzetal.°” suggest that the assessment of erbB-2 status can
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be used to identify patients at high risk of disease progression who would
benefit from adjuvant erbB-2 targeted mono- or combined therapy after
radical cystectomy.
7.4: Oestrogen Receptor B (ER B)
ERexpression in muscle invasive urothelial carcinomais a poorly
understood entity. ER @ staining is absentin all urothelial tissues. There was
a complete absence of ER a expression acrossall disease stages and the
benign urothelium. ER loss significantly heralds onset of malignancy and
is almost completely lost in muscle invasive urothelial carcinoma. Thisis in
1.7? who found higher number ofpositive ERsincontrast to Kaufmannet a
invasive tumours in comparison with non-muscle invasive urothelial
carcinoma. Basedon ourobservations, ER B appears to have a
cytoprotective effect with loss of ER B expression implying carcinogenic
 
 
transformation.
Benign Non muscle Muscle
urothelium invasive invasive
ER a* n 2 91 12
% 0% 0% 0%
ER B n 19 173 28
% 42% 21% 4%       * all ER a stained tissue were negative
Table 7.2: Extent of Oestrogen receptor expression Vs tumourstage
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7.5: Disease progression: Non-Muscle Invasive urothelial carcinoma to
muscle-invasive urothelial carcinoma
Rb, p21, PTEN and Hsp-27
Rb geneinactivation has been discussed in the previous Chapter. Studies
have observed Rb mutations in low-grade non-muscle invasive urothelial
carcinomaas well as high-grade muscle invasive urothelial carcinoma 48.
This ambiguity has been explained to a certain extent by the lack of
concordance between Rb nuclear immunoreactivity and the presence of a
functional protein. The use of Rb as an independent markerhas therefore
been limited. However,in this study, non-muscle invasive urothelial
carcinoma which progressed hadsignificantly (p<0.005) higher levels RB
expression. This defined sub-group of patients also showedsignificantly
higherlevels of p21, PTEN expression and under-expressionof hsp-27.
Thesethree closely related cell-cycle proteins suggest the possibility of a
specific gate/ check-pointin urothelial carcinoma transformation from non-
muscle invasive urothelial carcinoma to muscle invasive carcinoma.I have
tried to elucidate the reasons behindthese findings. The mainrestriction
controls in the cell-cycle are mediated by cyclins®”The D-type cyclins
(mainly D1) accumulate in the nucleus in the G, phase*®”. PTENprevents
38! Chung et al. suggest that nuclear PTEN —cyclin D1 nuclear localization
mediated down-regulation of cyclin-D1 transcription may modulate Go-G;
cell cycle arrest*®”. Sherr*®’ in his treatise on cancercell cycles hasy y
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elucidated these pathways. Hepoints out that the D-type cyclins; being
unstable, accumulation depends uponpersistent mitogenic signalling. This
in turn triggers the Rb phosphorylation resulting in the stunting ofits
growth-repressive functions***. However,thereis a shift in Rb
phosphorylation from mitogen-dependant cyclin D-cdk4/6 complexesto
mitogen-independant cyclin E-cdk2 which explains the loss of dependency
on extracellular growth factorsat the restriction point. The Cyclin E-cdk2
peaksat the G,-S check point after which Cyclin E degradesto be replaced
by cyclin A.
Therole of p21 in urothelial carcinogenesis has not been extensively
studied. We foundsignificantly higher expression levels of p21 (p<0.005) in
the non-muscle invasive urothelial cancer who progressed. p21isa
memberof the Cip/Kip polypeptide inhibitor family and was thought to be
385opposedto the action of cdks**’. However, studies which revealed both
p21°"' and p27‘! to be componentsofactive cyclin-CDK complexes**”
1°”! promotes the cyclin D-CDK4 complexes in-vitro’®’388" and also that p2
have necessitated a rethink about p21. Alt et al.**’ demonstrated that oir
promoted nuclear accumulation of cyclin D1-CDK4. These three major
biomarkers havecritical roles in urothelial carcinoma progression to
invasive disease through their action on the Cyclin D complexes (Figure
7.4).
Heat shock protein 27 (Hsp-27) wasoriginally discovere as an oestrogen-
modulated protein in breast cancer’mo identified to contribute to
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apoptosis””’.It is a low-molecular weight Hsp; part of a family of highly
homologouschaperoneproteins, ubiquitously expressed in multiple tissues
in response to environmental, physical, and chemicalstresses. It has been
found to be a culprit in breast*>’, cervical**’ and prostate cancer®”'.
Hsp-27 protects the cytoskeleton*”’, regulates the serine/threonine kinase
1°”? and other pathwaysimplicated in thesignalling molecule for cell surviva
cancercell survival and resistance*”*. This study shows a down-regulation
of hsp-27 in the secondary muscle invasive urinary bladders. This suggests
that overexpression of hsp-27 might have urothelial stabilising function
preventing progression. Hsp-27 hasbeenreported to have role in the
treatment of malignant disease; increased expression linked to vincristine
resistance in gastric cancer’, 5-fluorouracil resistance in colon cancer*”
and breast cancercells whichinitially over- expressed Hsp-27 became
sensitive to doxorubicin after modulation of endogenous Hsp-27 levels by
paclitaxel’re
Not only is Hsp-27 considered a powerful biomarker of aggressive cancers,
butit has also been mootedas a therapeutic target in order to render the
urothelial cells more tolerant to chemotherapy/ radiotherapy. Studies have
identified areas of interest such as inhibition of tumourcell migration by
blocking protein kinase C-dependent phosphorylation of Hsp-27°°7 inducing
mitotic arrest and enhancing apoptosis’; p38 MAPK/MAPK-activated
protein kinase 2 (MK2)inhibitors that inhibit phosphorylation ofits
399TT;downstream target- Hsp-2 inhibition of Hsp-27 phosphorylation at Ser’®
and Ser*’ by the MAPKAPkinase MKSprevents F-actin reorganisation that
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is necessary forcell migration”, However, further studies are needed to
ascertain whether anti-hsp-27s might accelerate disease progression if it has
already beeninitiated.
Assembly & p27Kip) A p2IKipl -()Sequestration i
v/
E-cdk2
Cyclin D So N\
Mitogenic mmm Dependent Rb Cyclin ESignals Kinases E2F JS\ Cyclin A
& other S phase genes
Figure 7.4: Cip/Kip proteins and cyclin cdks and Rb*®?
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Chapter8:
Conclusion
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Primary bladder cancers are genotypically and phenotypically heterogenous;
in commonwith other malignancies*”' 40An individual phenotype is
controlled by molecular signals that determine the frequency and amplitude
of transcription for individual genes. A protein product encoded by one gene
maycross-regulate expression of other genes. Also protein expression is
variable and also could be regulated by other genes or have involvementin
multiple pathways. This study has focused on identifying the molecular
portraits of humanurothelial carcinoma with the objective of correlating
patterns of gene expression with clinical outcome. The expression of
functional groups of genes have providedthe basis for separating bladder
tumours according to micro-anatomical location 8° So that particular gene-
expression profiles characterizing each stageidentify a biological
phenotype, thus providing evidence for the phenotype-modulating effects of
local environment.
The data obtained during this study confirmsthe initial hypothesis that
immunophenotyping individual human urothelial neoplasms provides new
predictive information on clinical behavior and outcomethatis not
otherwise obtainable from conventional morphology. Someof these data
support, andsignificantly extend, the findings of severalearlier studies'!? °°
383 403-405 This study also provides new information on the phenotypic
events within urothelial carcinomas suggesting that the ability to predict
clinical behavior or responseto therapeutic intervention would be greatly
improved with the benefit of biomarkerprofiling. Over a longer period of
time, the traditional classifications may needto be altered to take into
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account those patients with poor prognosis/ aggressive phenotype which
would needearlier radical treatment. In analyzing the panel of tumour
markers, we studied the effect of the biomarkers on an individual basis
despite understanding that cellular pathways frequently overlap and are
inter-woven. Wefelt that it would be more effective if a single or dual panel
of markers could be found to improve the prognostic accuracy.
Elevation of the rate of tumourepithelial cell proliferation, using Ki-67,
significantly correlates with, and predicts, individual tumourprogression for
somevariable amountoftime prior to progression becomingclinically
apparent. However,this is not a simple relationship since the onset of
tumourproliferationis likely to depend upon a multiplicity of different
factors.
Assessmentof tumour suppressor genes p53, pRb, p21 and PTENrevealed
altered patterns of expression that are tumour-specific and hence contribute
to determiningthe biological andclinical behavior of individual tumours. Of
301 cases studied, 181 (60%) revealed a probable mutation in the p53 gene.
This finding corresponds with the previously-published studies of Zlotta et
al.'?° and Sarkis et al.'*!. However,in manyofthe studied cases, expression
of mutated p53, located on chromosome 17p, appear to be both gradual and
heterogeneous. Typically, in these cases, the mutation appeared tooriginate
in the basal layers of papillary tumours or premalignant epithelium and to
extend through proximal layersof cells but disappearing from thecells
located two or three layers from the surfaceof the particular epithelium. The
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data indicate that, although p53 mutation is an early event in the genesis of
manyurothelial neoplasms,it is not an initiating event since a numberof
morphologically well-defined papillary lesions did not express p53 until
later in the genesis of these lesions. Immunophenotypic detection of mutated
p53 is potentially problematic, depending uponthe particular antibody and
the structural location of the specific epitope to which that antibodyis
directed***. Mutations are knownto occur at manysites within the p53 gene.
However, it is not known whetherall mutated p53 proteins, irrespective of
the location of the mutation, behave in an identically inefficient manner or
whetherdifferent mutations determine distinct patterns of molecular
behavior within affected cells. Detailed analysis in this thesis has been
restricted to p53 as an individual marker. We foundsignificant up-
regulation of p53 expression from benign urothelium to non-muscle
invasive urothelial carcinoma. The credence applied to the double hit theory
is due to the the observed lowerlevels of p53 in muscle invasive disease.
Of the 300 casesstudied, only 89 (30%) revealed loss of pRb. Rb loss was
found to indicate carcinomatousde-differentiation. We were unable to find
an association with stage. However, the percentage of biopsies that were
both p53 and Rb mutated increased with worsening stage. Likewise, in p21
studies; this study failed to show significant association with stage but
detailed higher expression levels in muscle invasive disease. Both these
markers showedsignificant variation between the expression levels n
normal tissue in comparison with malignant biopsies. The pattern of
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expression was almostreciprocal with Rb loss mirrored by p21 gain across
the urothelial cancer spectrum.
 
P53+Rb+ P53+ P53-ve P53-veRb-ve
Mutated Rb-ve Rb+ Non-mutated
Dysplasia, CIS, pTa 48 32 35 13
pTl 32 8 7 4
Muscle invasive 13 6 8 1       
Table 8.1: Four-group (p53 and Rb) expression patterns by stage of disease
Tumour suppressor gene PTEN,located on chromosome 10g, typically
revealed a biphasic expression during evolution and progression of
individual bladder cancersthat is reminiscent of the expression of PKC-B in
406Tn non-neoplastic urothelium, irrespective of theprostate cancers
presenceof inflammation, PTENis characteristically expressed throughout
the lower layers of the epithelium. However,as in-situ neoplasia develops
(pathological stage pTa), the intensity of urothelial expression diminishes
and disappears. However, with subsequent stromal invasion, re-expression
of PTEN occurs in the invading cells and is frequently stronger than in the
corresponding non-neoplastic epithelial cells.
This study revealed a subset of non-muscle invasive urothelial carcinoma
patients (despite low numbers) who behaved in distinctly different pattern
to others. These patients expressed significantly higher levels of pRb, p21
and PTENandloss of hsp-27 suggesting a higher risk of developing
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invasive muscle-invasive disease. These four biomarkers could be useful in
identifying a subset of patients with non-muscle invasive urothelial
carcinoma who havehigherrisk of progression to muscle invasive disease.
These patients would be better served by earlier radical treatment than being
treated with immunotherapy.It is difficult to define criteria based on these
low numbers. However,it would notbe easier to garner larger numbers of
this specific sub-cohort as the evidential trend has been to considerearly
radical treatment.
Bcl-2 expression levels were highly significant within benign urothelium
and loss of expression wasseen early as a marker of malignantdisease.
Significant correlation was seen with stage. Bcl-XL expression levels were
difficult to assess as the positive levels were low across the cohort.
However, muscle invasive urothelial carcinoma showedsignificant over-
expression. This suggests that Bcl-X1 over-expression could imply eithera
poor prognosisorresistance to urinary bladder conserving therapeutic
measures
ErbB-2 loss wassignificant within muscle invasive urothelial carcinoma.
ErbB-2 down-regulation could have a role in identifying patients with non-
muscle invasive who would benefit from earlier radical treatment.
ER f appears to have a cyto-protective effective, with significant down
regulation seen in malignanttissue. There was an inverse correlation of
expression with tumourstage.
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The phenotypic classification of urothelial tumours could be based on the
four-group expression patterns of p53 and Rb. Other genes such as p21, p16,
erbB-2, bcl-2 and PTEN would be used within each group for sub-group
analysis.
In this study cohort, the urothelial biopsies which had no abnormality
detected or had chronic inflammation in patients with a history of urothelial
carcinoma wereanalysedasa different entity. These histopathologically
normalurothelial biopsies have a distinctly separate biomarkerprofile in
comparison with true malignancy or benign urothelium. This suggests that
urothelial carcinomais associated with field changes rather than specific
focal entities. Once urothelial carcinomahas occurred, the urothelium is
unstable with persistent degree of flux and needs to be monitoredforlife.
Changesin the biomarkerprofile should trigger the clinician to re evaluate
managementplansfor the patient especially in the suspected transition from
pT, disease to muscle invasive urothelial carcinoma.
The biomarkerprofile of the ‘no abnormality detected/ chronic
inflammation with a history of urothelial carcinoma’ group raise more
dilemmasthan answers with regards to the managementand follow-up for
non-muscle invasive bladder cancers. These findings imply that the use of
conventional white-light cystoscopy is inadequate to diagnose these
urothelial entities (not true-benign urothelium) which are not only pre-
visible but also pre-histological lesions. Clinicians have realized the
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inadequaciesofthe present protocols and tools; and havetried to improve
diagnostic capabilities with the use of various technological developments
such as narrow-band imaging cystoscopy” and fluorescentlight/
408photodynamic diagnostic cystoscopy’. Howeverthe results have been
disappointing.
Weneedto consider a moreradical follow-up program for patient with
conservatively managed urothelial carcinoma. Despite there being no
features of macroscopic (cystoscopic) or microscopic (histological); the
presence of biomarkerprofiled abnormal urothelium in comparisonto the
benign platform suggests that it might be prudent to considerurothelial
carcinomapatients for annual/ bi-annual random biopsies with a run of
biomarkerprofiling and consequent revaluation of further management/
follow-up dependanton the favorability of the biomarker expressionprofile.
Weare suggesting a similar evolution in managing non-muscle invasive
urothelial carcinomapatients; similar to the modulated approach in
conservative managementof prostate cancer where annual PSA follow-up
with watchful waiting has been replaced by annual/ 18-monthly prostate
biopsies and an active surveillance program.
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Summary
e This study has confirmed the “proofof principle” that routine
immunophenotypingprovides valuable pathological information
importantto the effective and biologically-appropriate clinical
managementof patients with bladder neoplasms.
e Neoplasia is confirmed and distinguished from inflammatory and other
non-neoplastic conditions by loss of bel-2 frequently accompanied by
decline in expression of PTEN.
e The urothelium should be considered unstable once malignancy has
been established suggesting the need for long-term probably life-long
surveillance.
e Tumouraggressivenessis predicted by elevated rates of tumourcell
proliferation as measured by Ki-67 assessment.
e Both papillary carcinomasand flat malignancies can be more accurately
classified according to immunophenotyping expression characteristics
than by morphologyalone. Important parameters include p53 and pRb
status that togetherplace all bladder carcinomasinto four genotypic and
phenotypic groups with greater biological relevance than any unassisted
morphologicalclassification.
e Pathological staging of early malignancies, with more accurate
recognition of micro-invasive disease (pT 1a) rather than neoplasia
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restricted to the epithelium (pTa) may be obtained by detection of hsp-
27 expression.
There appears to be a two distinct disease entities; non-muscle invasive
and muscle invasive urothelial carcinoma. These two types show
differing biomarker profiles which would help predict high risk non-
muscle invasive disease (Mutated p53 and Rb, p21 and PTEN with loss
of hsp-27).
Three groups of genes can be established for phenotypic classification:
1. Genes for Classification: Rb and p53
Modifiers: PTEN
2. Distinguishers: Malignant from benign--- erb B-2 and bcl-2
3. Hsp-27: Not as useful in the urinary bladder but helpsto identify
invasion and thus makes pTato pT
The use of antibodies is time-consuming, imprecise with respect to
certain antigens, labour-intensive and consequently the technique can
be employed to examine expression of onlya relatively few
determinants.It is suggested, therefore, that molecular biological
approachesare developed by whichthe findings ofthis study are
extendedto the analysis of the expression of a muchlarger range of
selected genesin orderto routinely expression-profile all bladder
carcinomasand then obtain more accurate predictive assembly of
individual cancers.
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